Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 1 of 67 
  
 
TITLE PAGE  
 Protocol Title:   
A Comparative Crossover Study on the Safety, Efficacy, and Patient  Quality of Life Comparing 
PureWick ™ System  with an Established Comparator in the Home Setting for Incontinence 
Overnight  
 Protocol Number: UCC -8007 
 Version Number: 5.0   Investigational Device : PureWick ™ System   
 Study Type: Post- Market  
 Short Title: PureWick ™ At -Home Pi[INVESTIGATOR_690333]: C. R. Bard, Inc., a subsidiary of Becton, Dickinson and Company  Legal Registered Address:  C. R. Bard, Inc. 
 [ADDRESS_936465]. 
 Covington, GA [ZIP_CODE] 
 Legal European Representative:  BDI Benelux   
   Hagelberg [ADDRESS_936466]:  SengDao VanMany Senior Clinical Project Manager  
[ADDRESS_936467]  
Vernon Hills, IL [ZIP_CODE] [EMAIL_13152]
 
([PHONE_14329] (w) ([PHONE_14330] (c)  
 
Regu latory Agency Identifier Number(s):  [STUDY_ID_REMOVED] (US A), IDRCB: 2023-A01727-38 
([LOCATION_009])   
 
Overall Rationale for the protocol version 5.0:  
Protocol revised  to incorporate new Quality of Life questionnaires (PROMIS Sleep Disturbance 
and End of Study Participant Preference Survey).  
 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 2 of 67 
  
Revision History  
Version Number  Date  Type  
1.0  30 Jan 2023  Original  
2.0 26 June 2023  Protocol update to allow 
inclusion of up to two 
investigational sites in both [LOCATION_009] and  the US; 
administrative updates to correct and clarify text.  
3.[ADDRESS_936468] 2023 Changes incorporated based 
on recommendations from the National  Competent authority 
ANSM  during their review: 
• Added Estimated start and 
end date of the study 
• Added IDRCB number 
4.0 5 September 2023 Changes incorporated based 
on recommendations from the leading French etic committee during their review:  
• Added an additional exclusion criteria:  Participants under 
supervision of a legally 
authorized representative  
are excluded to participate in the UCC-8007 trial 
• Deletion  of the possibility 
for the home nurses to conduct virt ual visits  
instead of face- to-face 
visits  at day 30 
5.0 08 April 2024 Changes incorporated based 
on recommendations to include the following questionnaires: 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 3 of 67 
 • Validated English and 
French version of the 
PROMIS Sleep Disturbance  
Questionnaire  
• End of Study Participant Preference Survey 
  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   [ADDRESS_936469] Manager  Winfried Huesmann  
Clinical Program  Manager, 
EMEA  This document is signed electronically in the eTMF system  
   
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936470] sign the Clinical 
Study Agreement (CSA) and obtain written approval from the appropriate Institutional 
Review Board (IRB)/Ethics Committee (EC).  
2. The Investigator must receive BD -sponsored training prior to site activation. The 
Investigator is responsible for ensuring that all Sub- Investigators and clinical staff are 
adequately trained prior to performing any data collection or study- related procedu res.   
3. The Princip al Investigator shall ensure that the study is conducted in accordance with the 
study protocol, any modifications as requested by [CONTACT_1201]/EC, the signed CSA, the ethical principles of the Declaration of Helsinki, Good Clinical Practice (ICH E6) / ISO [ZIP_CODE]), and applicable national/regional regulations and laws.  
4. If applicable, ensure that written informed consent is obtained from each participant prior 
to the conduct of any study procedure, using the current IRB/EC approved Informed 
Consent Form.  
 
I have read and understand the contents of this  study protocol. I agree to follow and abide by [CONTACT_270872]. I agree to conduct the  trial in accordance with 
the study protocol, the signed Clinical Study Agreement, the signed Investigator Agreement  and 
Good Clinical Practice (GCP) as well as applicable FDA and ISO regulations (e.g.,  21 CFR 
Parts  50, 54, 56 and 812; 21 CFR Part 812.28 (a) (1) (Good Clinical Practice) ; EU MDR (Council 
Regulation 2017/745 of 5 April 2017),  MDCG gu idelines, and applicable national and regional 
law and regulation. I agree to participate in  BD-Sponsored training prior to performing any data 
collection or  study- related procedures.  
 
Agreed to by (Investigator):   
   _______________________________________________  Printed Name – Investigator    
  
 _______________________________________________  
Signature – Investigator   
 
 ______________________  
 Site Number  
 
 _______________________________________________  Date   
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 6 of 67 
  
TITLE PAGE  .................................................................................................................................. 1 
Abbreviations  ................................................................................................................................ 10 
1.0 PROTOCOL SUMMARY .................................................................................................... 12 
1.1 Synopsis  .............................................................................................................................. 12 
1.2 Schema  ................................................................................................................................ 19 
1.3 Schedule of Activities  ......................................................................................................... 20 
2.0 INTRODUCTION  ................................................................................................................ 23 
2.1 Background  ......................................................................................................................... 23 
2.3 Rationale .............................................................................................................................. 24 
2.4 Risk/Benefit Assessment  ..................................................................................................... 24 
2.5 Risk Assessment  .................................................................................................................. 25 
2.5.1 Benefit Assessment  .......................................................................................................... 27 
2.5.2 Overall Benefit: Risk Conclusion .................................................................................... 28 
3.0 OBJECTIVES AND ENDPOINTS  ...................................................................................... 28 
4.0 STUDY DESIGN .................................................................................................................. 29 
4.1 Overall Design..................................................................................................................... 29 
4.2 Scientific Rationale for Study Design ................................................................................. 30 
4.3 Participant Input into Design............................................................................................... 30 
4.4 End of Study Definition ...................................................................................................... 30 
5.0 STUDY POPULATION  ....................................................................................................... 30 
5.1 Inclusion Criteria  ................................................................................................................. 31 
5.2 Exclusion Criteria  ................................................................................................................ 31 
5.3 Lifestyle Considerations  ...................................................................................................... 31 
5.4 Screen Failures  .................................................................................................................... 31 
6.0 STUDY INTERVENTION(S)  .............................................................................................. 32 
6.1 Investigational/Test Device  ................................................................................................. 32 
6.2 Pre-placement Procedure  ............................................................................................ 32 
6.3 Control Device/Standard of Care  ........................................................................................ 33 
6.4 Pre-placement Procedure  ............................................................................................ 33 
6.5 Ancillary Devices/Products  ................................................................................................. 34 
6.6 Device Labeling  .................................................................................................................. 34 
6.7 Treatment Allocation and Measures to Minimize Bias  ....................................................... 35 
6.8 Randomization ............................................................................................................ 35 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 7 of 67 
 6.8.1  Blinding/Masking  ................................................................................................... 35 
7.0 STUDY PROCEDURES AND ASSESSMENTS  ................................................................ 35 
7.2 Screening and Enrollment  ................................................................................................... 36 
7.2.1  Informed Consent .................................................................................................... 36 
7.2.2  Eligibility  ................................................................................................................ 36 
7.2.3  Enrollment/ Assignment of Participant Number ..................................................... 36 
7.2.4  Randomization ........................................................................................................ 36 
7.2.5 Home Nurse Introduction ............................................................................................ 37 
7.2.7 Days 2- 7 ........................................................................................................................... 38 
7.2.8 Day 8  ................................................................................................................................ 38 
7.2.9 Days 9- 14 ......................................................................................................................... 38 
7.2.10 Day 15  ............................................................................................................................ 38 
7.2.11 Days 16- 21 ..................................................................................................................... 38 
7.2.12 Day 22  ............................................................................................................................ 38 
7.2.13 Days 23- 28 ..................................................................................................................... 39 
7.2.14 Day 29  ............................................................................................................................ 39 
7.2.15 Day 30  ............................................................................................................................ 39 
7.2.16 Days 29- 42 (+14) Wash Out Period  ............................................................................... 39 
7.2.17 Treatment Phase 2  .......................................................................................................... 39 
7.3 Safety Assessments  ........................................................................................................ 39 
7.3.1 Draize Scale  ................................................................................................................. 39 
7.4 User Preference Questionnaire ............................................................................................ 40 
7.5 Participant Follow -Up ......................................................................................................... 41 
7.6 Replacement of Participants  ................................................................................................ 41 
8.0 PARTICIPANT DISCONTINUATION/WITHDRAWAL .................................................... 41 
8.1 Discontinuation/Withdrawal  ............................................................................................... [ADDRESS_936471] to Follow -Up ............................................................................................................... 41 
9.0 ADVERSE EVENTS AND DEVICE DEFICIENCIES  ........................................................ 42 
9.1 Definitions of Events  ........................................................................................................... 42 
9.1.1 Adverse Events (AEs)  .................................................................................................. 42 
9.1.2  Serious Adverse Events (SAEs) .............................................................................. [ADDRESS_936472] (ADE) / Serious Adverse Device Effect (SADE)  .............. 43 
9.1.4  Unanticipated (Serious) Adverse Device Effect (UADE/[LOCATION_003]DE)  ........................ 43 
9.2 Severity of Adverse Events  ................................................................................................. 44 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 8 of 67 
 9.3 Relationship of Adverse Event to Device(s)/Procedure  ...................................................... 44 
9.4 Reporting of Events  ............................................................................................................. 46 
9.5 Serious Health Threats  ........................................................................................................ 47 
9.6 Safety Committees  .............................................................................................................. 48 
9.7 Device Deficiencies ............................................................................................................. 48 
10.0 STATISTICAL METHODS  ................................................................................................. 48 
10.1 Overview of Study Design ................................................................................................ 49 
10.2 Sample Size Considerations  .............................................................................................. 49 
10.3 Analysis Population ........................................................................................................... 49 
10.4  General Considerations  .................................................................................................. 49 
10.4.1 Handling of Missing Data  .......................................................................................... 49 
10.4.2 Poolability of Data  ..................................................................................................... 50 
10.4.3 Multiplicity Control  ................................................................................................... 50 
10.5 Primary Endpoint(s)  .......................................................................................................... 50 
10.6  Secondary Endpoint(s)  ................................................................................................... 50 
10.6.1 Questionnaire Nocturia Quality of Life  (N-QoL)  ...................................................... 50 
10.6.2  Questionnaire PROMIS Sleep Disturbance  ............................................................ 51 
10.6.3  Tolerability -  Number of days of actual use  ........................................................... 51 
10.6.4  Tolerability -  Discontinuation rate due to device discomfort or inconvenience  ..... 51 
10.6.5  Comfort, Ease of Use and Confidence  .................................................................... 51 
10.7 Tertiary/Exploratory Endpoint(s)  ...................................................................................... [ADDRESS_936473] Retention  ............................................................................................................... 52 
12.0  QUALITY CONTROL AND ASSURANCE  ...................................................................... 53 
12.1 Control of Study Products  ................................................................................................. 53 
12.2 Monitoring ......................................................................................................................... 53 
12.3 Audits and Inspections  ...................................................................................................... 54 
12.4 Protocol Deviations  ........................................................................................................... 54 
13.0  ADMINISTRATIVE REQUIREMENTS  ............................................................................ 55 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 9 of 67 
 13.1 Investigator and Site Selection  .......................................................................................... 55 
13.2 Training ............................................................................................................................. 55 
13.3 Required Documents  ......................................................................................................... 55 
13.4 Publication Policy  ............................................................................................................. 56 
13.5 Study Registration  ............................................................................................................. 56 
13.6 Termination of Study ........................................................................................................ 56 
14.0 ETHICAL AND REGULATORY CONSIDERATIONS  .................................................... 57 
14.1 IRB/EC Approval  .............................................................................................................. 57 
14.2 Informed Consent and Confidentiality .............................................................................. 57 
14.3  Confidentiality  ........................................................................................................ 58 
14.4 Regulatory Status  .............................................................................................................. 58 
14.5 Statement of Compliance  .................................................................................................. 58 
15.0  REFERENCES  ..................................................................................................................... 59 
16.0  APPENDICES  ...................................................................................................................... 61 
Appendix 1 : Draize Scale for Skin Irritation  ........................................................................... 61 
Appendix 2: Katz ADL assessment Score  ................................................................................ 61 
Appendix 3: PureWick™  Female External Catheter Instructions for Use PWFX30 (US)  ...... 61 
Appendix 4: PureWick™  Female External Catheter Instructions for Use PWFX30E (EU)  .... 61 
Appendix 5: PureWick™  Urine Collection System Instructions for Use PW100 & PW 200 
(US) 61 
Appendix 6: PureWick™  Urine Collection System Instructions for Use PW200E (EU)  ........ 61 
Appendix 7: Hollister® Female Urinary Pouch External Collection Device Instructions for 
Use 61 
Appendix 8: N -QOL English  .................................................................................................... 62 
Appendix 9: N -QOL French  ..................................................................................................... 62 
Appendix 10: PROMIS English ................................................................................................ 62 
Appendix 11: PROMIS French  ................................................................................................. 62 
Appendix 12 : Participant Comfort Questionnaire PureWick™ System (Sample)  .................. 62 
Appendix 13 : Participant Comfort Questionnaire Hollister® Female Urinary Pouch External Collection Device (Sample)  ...................................................................................................... 63
 
Appendix 14 : PureWick ™ System Participant Ease of Use Questionnaire (Sample)  ............. 64 
Appendix 15: Hollister® Female Urinary Pouch External Collection Device Participant Ease of use Questionnaire (Sample)  .................................................................................................. 65
 
Appendix 16: End of Study Participant Preference Survey (Sample)  ...................................... 66 
 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936474], Inc.  
BD Becton Dickinson and Company  
CFR  Code of Federal Regulations  
CI Confidence Interval  
CMP  Clinical Monitoring Plan  
CRF  Case Report/Record Form  
CRO  Contract Research Organization  
CV Curricul um Vitae  
DMP  Data Management Plan  
eCRF  Electronic Case Report Form  
EDC  Electronic Data Capture  
FDA  Food and Drug Administration  
FDAAA  FDA Amendments Act of [ADDRESS_936475]  
IAD Incontinence Associated Dermatitis  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IRB/EC  Institutional or Independent Review Board/Ethics Committee  
MDCG  Medical Device Coordination Group  
MDR  Medical Device Regulation  
NDA  Non-disclosure Agreement  
NSR Non-significant Risk  
OAB  Overactive Bladder Syndrome  
PI [INVESTIGATOR_690334] ™ Urine Collection System  
PW  PureWick ™ Female External Catheter  
N-QOL  Nocturia Quality of Life  
QOL  Quality of Life  
RCT  Randomized Control Trial  
RMV  Routine Monitoring Visit  
SADE  Serious Adverse Device Effect  
SAE  Serious Adverse Event  
SD Standard Deviation  
SIV Site Initiation Visit  
SFTP  Secure File Transfer Protocol  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936476]  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 12 of 67 
 1.0 PROTOCOL SUMMARY 
 
1.1 Synopsis  
 
Protocol Title  A Comparative Crossover Study on the Safety, Efficacy, 
and Patient Quality of Life Comparing PureWick ™ System 
with an Established C omparato r Overnight in the Home 
Setting for Incontinence.  
Short Title  PureWick ™ At -Home Pi[INVESTIGATOR_690335] , which will aid reimbursement in  [LOCATION_009] and 
the [LOCATION_002]  (U.S.). This pi[INVESTIGATOR_690336].  
Objectives and Endpoints 
 Objective(s)  Endpoint(s) 
Primary  
To compare efficacy 
and safety of PureWick ™ System  
and Hollister
® Female 
Urinary Pouch External Collection Device  Primary  
• Efficacy – Daily  capture 
rate via bed pad weights 
and captured volume. 
 
• Safety – Daily  skin 
irritation score using the 
Draize Scale .  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 13 of 67 
 Secondary  
• To assess impact of 
PureWick ™ System 
and Hollister® Female Urinary 
Pouch External Collection Device  on 
Nocturnal Incontinence related Quality of Life and Sleep  
 
• Tolerability – To assess the tolerance of PureWick ™ 
System  and 
Hollister® Female Urinary Pouch External Collection Device over the expected duration of use  
 
• To assess participant 
comfort and ease of use of PureWick ™ 
System and Hollister® Female Urinary Pouch External Collection Device  
 
• To assess participant  
preference between  
the PureWick ™ 
System and Hollister® Female Urinary Pouch External Collection Device after study 
completion  Secondary  
• Nocturia Quality of L ife 
(N-QOL)  score collected 
at baseline and every 2 
weeks  during treatment  
• PROMIS Sleep Disturbance score at 
baseline and every 7 th 
day during treatment. 
 
 
• Tolerability – Number of 
days of actual use of both devices & Discontinuation rate attributed to the device’s inconvenience or discomfort. 
 
  
• Overall comfort  and ease 
of use scores on a 5-point 
Likert scale (brief questionnaire) collected at the end of each treatment phase.  
 
• Overall preference via end of study participant preference survey administered at study completion. 
 
 
 
Design and Overview In this prospective, open -label, c rossover trial, 
approximately  30 women with Nocturnal  Urinary 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 14 of 67 
 Incontinence requiring the use of diapers in bed will be 1:1 
randomized to a treatment sequence using two devices 
(PureWick ™ System and Hollister® Female Urinary Pouch 
External Collection Device) and followed for approximately 10 weeks through 2 treatment phases. For purposes of this study, the PureWick ™ System will be referenced to include the PureWick ™ Female External Catheter used in 
conjunction with the PureWick™ Urine Collection System, including the tubing and the canister . 
At the start of the study, participant s will be consented and 
screened against inclusion/exclusion criteria. All subjects that have met all eligibility criteria will be assigned a treatment order. Participants will view the training video for the applicable product at the beginning of each treatment phase and have access to the Instructions for Use ( IFU) to 
review. Participant s will use the device assigned in 
treatment phase 1 overnight while sleepi[INVESTIGATOR_48908] 4 weeks (28 days) before transitioning to the second assigned device in treatment phase 2.  
The primary endpoints will evaluate safety (skin injury) and efficacy (capture rate). Safety will be evaluated using the Draize Scale and efficacy will be measured based on daily capture rate.  
 Nurses  will visit daily to measure urine capture rate and to 
assess for skin irritation  using t he Draize Scale.   
The secondary outcomes include participative  evaluation of 
the therapy and self ‐reported changes  using questionnaires  
and preference surveys : Nocturia Quality of Life (N -QOL) 
assessment  evaluated at baseline (previous treatment) and 
every 14 days  through completion of each treatment phase 
(4 weeks/ 28 day period),  PROMIS Sleep Disturbance 
measured at baseline and every 7 days through completion 
of each treatment phase,  surveys  (comfort  & ease of use)  
completed by [CONTACT_690350] 4- week  period , and 
end of study participant preference survey collected at study completion.   
Tolerability to be measured by [CONTACT_690351], and discontinuation rate attributed to the device’s discomfort or inconvenience.  
Investigational Device  Test product(s):   
• PureWick ™ Female External Catheter ( PWFX 30) 
(U.S.) and (PWFX30E) ( EU) 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 15 of 67 
 Protocol Title  A Comparative Crossover Study on the Safety, Efficacy, 
and Patient Quality of Life Comparing PureWick ™ System 
with an Established C omparato r Overnight in the Home 
Setting for Incontinence.  
• PureWick ™ Urine Collection  System  (PW100 , 
PW200) (U.S.) and (PW200E) (EU)  
For regulatory status, refer to Regulatory Status row 
below within this table.  
Reference/Comparator product(s):   
Marketed Device: Hollister® Female Urinary Pouch External Collection Device  
Ancillary Product(s):    
• PureWick ™ replacement  Kit (PWKIT03) (U.S.) and 
(PWKIT03E)  (EU)  
• Absorbent under-pads 
• Medium/ Large sealing plastic bags  
• Medical Triangular Graduated Cylinders, 1000mL 
• Weighing Scales  
• Urine Collection Bags  for Hollister FUP  
• Urine Bag Holders 
• Mesh underwear  
• PPE (Gloves, Chux)  
• Barrier Paste  
• Wipes  
• Micropore tape  
• Hair trimmers/clippers  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 16 of 67 
 Participants  Adult female participants currently using incontinence 
products at night (e.g., nocturnal enuresis, nocturia, 
mobility limitation) will be recruited for this study from the  
study site.  
To best mimic potential users of the PureWick ™ System, 
participants >[ADDRESS_936477] 90% of participants are >[ADDRESS_936478] meet all of the following criteria: 
1. Adult Female Participant s >18 years of age at the 
time of signing the informed consent. 
2. Currently use diapers or equivalent at night for urine capture (“Change complet” ( FR))  
3. Willing to comply  with all study procedures in this 
protocol.  
4. Provision of signed and dated informed consent form . 
 
 
Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply: 
1. Has frequent epi[INVESTIGATOR_690337] a fecal management system in place; or  
2. Has moderate to heavy menstruation and cannot use a tampon or menstrual cup; or 
3. Has Urinary tract, vaginal or other chronic infections, active genital herpes; or  
4. Has Urinary retention; or 
5. Is agitated, combative, and/or uncooperative and may remove the external catheter or pouch; or  
6. Has any wound, open lesion or irritation on the genitalia, perineum, or sacrum; or 
7. Has any pre-existing neurological, psychiatric, or other condition that would confound quality of life assessment or would make it difficult to self -report 
on quality-of-life questionnaires in the opi[INVESTIGATOR_871]; or 
8. Is known to be pregnant at time of enrollment (for 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 17 of 67 
 Protocol Title  A Comparative Crossover Study on the Safety, Efficacy, 
and Patient Quality of Life Comparing PureWick ™ System 
with an Established C omparato r Overnight in the Home 
Setting for Incontinence.  
women of childbearing age); or  
9. Any other condition that, in the opi[INVESTIGATOR_1070], would preclude them from participating in the study. 
10. Is under supervision of a legally authorized representative  
Intervention(s)/Procedure(s)  The PI [INVESTIGATOR_1461]/ nurse  defined by [CONTACT_690352]. Participants assigned to both treatment arms will place and remove the FEC (female external catheter) or FUP (Female Urinary  Pouch) after standardized teaching is 
completed on the first day of the treatment phase.  
Participants will use the device assigned in treatment phases 1 and 2 overnight while sleepi[INVESTIGATOR_48908] 4 weeks (28 days). There will be a minimum washout period of 2 weeks (not to exceed 4 weeks) between treatment phases.  
Investigational Sites  Approximately 2 site s in [LOCATION_009] and approximately 2 site s 
in the U.S. 
Data Monitoring Committee  N/A 
Regulatory Status Post- Market , Non -significant risk  
PureWick ™ System  
• Class I, non- sterile device , CE marked , currently 
marketed  in Europe 
• Class I, 510(k) exempt device currently marketed in 
the U.S. 
This investigation will use the PureWick ™ System for its  
intended purpose. 
Trial Duration  Estimated start date: (First Patient In): 19 Sep 2023 
Estimated end date (Final Clinical Study Report): October 
2024 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 18 of 67 
 Protocol Title  A Comparative Crossover Study on the Safety, Efficacy, 
and Patient Quality of Life Comparing PureWick ™ System 
with an Established C omparato r Overnight in the Home 
Setting for Incontinence.  
Regulatory Agency Identifier 
Number(s):  
 [STUDY_ID_REMOVED] ([LOCATION_003]) 
IDRCB: 2023-A01727-38 ([LOCATION_009])    
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 19 of 67 
  
1.2 Schema  
 
 
  

Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 20 of 67 
 1.3 Schedule of Activities  
Procedure Screening / 
Enrollment  Daily Study Home Visits  
Ph 1 
Baseline 
Day 1  Ph1 
Day 
2-14 Ph1 
Day 15 Ph1 
Day 
16-28 Ph1 
Day 29 Ph1 
Day 
30 Washout  
Day 29-42 
(+14 days)  Ph2 
Baseline 
Day 1 
 Ph2 
Day 
2-14 
 Ph2 
Day 
15 
 Ph2 
Day 
16-28 
 Ph2 
Day 
29 
 Ph2 
Day 
30 
Informed consent  X              
Inclusion and 
exclusion criteria  X              
Demography  X              
Medical history  X              
Katz ADL Index  X              
Partic ipant ID 
Assignment and 
Randomization  X       
       
Introduction to 
Home Nurses  
(On site or Virtual)  X       
       
Visual Skin 
Assessment & 
Draize Scoring  
(Both site and 
Nurses)   X X X X X X  X X X X X X 
Nurses Confirm 
Study Supplies   X       X      
Nurses Have 
Participant 
Complete N-QOL   X  X*  X*  
 X  X*  X*  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 21 of 67 
 Procedure Screening / 
Enrollment  Daily Study Home Visits  
Ph 1 
Baseline 
Day 1  Ph1 
Day 
2-14 Ph1 
Day 15  Ph1 
Day 
16-28 Ph1 
Day 29 Ph1 
Day 
30 Washout  
Day 29- 42 
(+14 days)  Ph2 
Baseline 
Day [ADDRESS_936479] 
Participant 
Complete 
PROMIS Sleep   X X* 
Day 8  X* 
Day 15  X* 
Day 22  X* 
Day 29   
 X X* 
Day 8  X* 
Day 15  X* 
Day 22  X* 
Day [ADDRESS_936480] 
Device Training 
w/Participants   X      
 X      
Nurses Pre -weigh 
urine canister or 
graduated cylinder   X      
 X      
Nurses Pre-Weigh 
Overnight Pads 
and Mesh 
underwear  
(if applicable)   X X X X   
 X X X X   
Participant s wear 
investigational 
device  X X X X   
 X X X X   
Nurses Measure 
Urine Output    X X X X    X X X X  
Nurses Post-Weigh 
Overnight Pads 
and Mesh 
Underwear  
(if applicable)    X X X X  
  X X X X  
Participant 
Completes 
Preference Survey       X*  
     X*  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 22 of 67 
 Procedure Screening / 
Enrollment  Daily Study Home Visits  
Ph 1 
Baseline 
Day 1  Ph1 
Day 
2-14 Ph1 
Day 15  Ph1 
Day 
16-28 Ph1 
Day 29 Ph1 
Day 
30 Washout  
Day 29- 42 
(+14 days)  Ph2 
Baseline 
Day 1 
 Ph2 
Day 
2-14 
 Ph2 
Day 
15 
 Ph2 
Day 
16-28 
 Ph2 
Day 
29 
 Ph2 
Day 
30 
Participant 
Completes End of 
Study Preference 
Survey         
     X*  
AE review  
(If applicable)    
SAE review  
 (If applicable)    
Device 
Deficiencies  
(If applicable)    
*To be completed per t reatment schedule or upon treatment discontinuation, whichever comes first.   
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 23 of 67 
  
2.0 INTRODUCTION 
 
The PureWick ™® Female External Catheter ( PureWick ™ FEC) is an external drainage 
device to address the need for an effective, non- invasive method of managing urine output 
in adult  incontinent women.  The device utilizes suction to drain urine away from the patient  
through tubing that is connected to a collection canister.  PureWick ™ FEC can use either 
wall suction (acute care setting) or a free- standing PureWick ™ Urine Collection System 
(home setting/skilled nursing facility).  In the U.S.,  PureWick ™ FEC is  a Class I, 510(k) 
exempt device. In Europe, t he PureWick ™ FEC is a Class I,  CE marked, non- sterile device . 
 
2.[ADDRESS_936481] on the individual, their family or caregiver, and the broader health system. Nocturnal enuresis in the adult population may be related to a multitude of causes, including but not limited to OAB (Overactive Bladder syndrome), dementia, mobility issues, and  nocturia
9. There is an apparent lack of research and focused attention on 
urinary incontinence management in people living at home.[ADDRESS_936482] adults with nighttime incontinence live.
3 
 
Current literature supports that incontinence is under -reported.9,13 One qualitative study 
looking at those with dementia and incontinence reported, “Most carers reported 
protecting the person's dignity by [CONTACT_690353] a crisis”2  and incontinent women were less likely to seek care for their 
incontinence compared with incontinent men.7  Not only are patients and their caregivers 
embarrassed to discuss incontinence with their provider, but they’re also embarr assed 
about the multiple challenges with available toileting supplies ,4 which has highlighted the 
need for urinary management solutions. In addition to being under -reported, older people 
frequently are not assessed and treated.13 
 
Although prevalence reports range, urinary incontinence (UI) rates among women are 
consistently high, especially in the elderly. The burden of UI amongst elderly people in 
the [LOCATION_002] (U.S.) is immense, with UI prevalence estimates for elderly commun ity-
dwelling women approximately 41% of Medicare beneficiaries11 ranging up to 55%.10 UI 
represents a similar public health burden in [LOCATION_009], with 25% to 40% of women declaring 
suffering from UI and an increasing prevalence with age, with UI rates exceeding 45% among 75+ year -old women.
28 
 Quality of Life (QOL) is impacted in women with UI,
13 including comorbidities and 
poorer health overall (despi[INVESTIGATOR_103850], poverty status, or smoking), including falls10 and 
positive bacterial cultures in those with UI in nursing homes5, physical and mental health 
(independent of demographic factors and comorbidities).8, and Incontinence Associated 
Dermatitis (IAD).12 These represent meaningful constraints in physical and social 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936483] is to empower elderly 
individuals with incontinence to stay in their own homes with a better quality of life is that 
they would require caregiver assistance during toileting regularly1, which adds additional 
expense. A recent Conjoint Analysis survey revealed that getting a good night’s sleep and 
feeling rested were most important to individuals with noctu rnal enuresis.[ADDRESS_936484] been derived from community- dwelling 
populations. 9,12 
 
Further research is needed to determine if there’s an unmet need for current solutions to identified problems such as the need for additional caregivers or admission to institutions, Quality of Life solutions, or product alternatives that are safe and effe ctive, and if there  is 
potential to improve quality of life, or delay nursing home admissions with alternative home care solutions. A recently published patient and caregiver satisfaction survey with the PureWick ™ System used in the home setting showed over 80% satisfaction, comfort, 
and ease of use using the product compared with their baseline incontinence solution despi[INVESTIGATOR_140566] 70% reporting the PureWick ™ System had a higher cost compared with their 
baseline direct costs.
25 
 
The PureWick ™ Urine Collection System ( PUCS) is to be used with PureWick™ 
External Catheters  (FEC)  which are intended for non- invasive urine output management 
and will be collectively referenced as the PureWick ™ System throughout this  study.  
 
2.[ADDRESS_936485]  clinical and quality of life data from patients requiring urine output 
management overnight in the home setting, which will aid reimbursement in  [LOCATION_009] and 
the [LOCATION_002]  (U.S.). This pi[INVESTIGATOR_690338] -setting, randomized control trial . 
  
2.4 Risk/Benefit Assessment  
 
Subjects participating in this study will be treated with approved, marketed devices and will use the investigational devices as intended. Therefore, subjects will be exposed to the same risks shared by [CONTACT_690354] a real -
world  setting.  More detailed information about the known and expected benefits and risks 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 25 of 67 
 and reasonably expected adverse events of the PureWick ™ Female External Catheter , 
PureWick Urine Collection System  and the Hollister ® Female Urinary Pouch External 
Collection Device may be found in the Instructions for Use  for each product . 
 
2.5 Risk Assessment  
 
Potential Risk of Clinical Significance   Summary of 
Data/Rationale for Risk  
 Mitigation Strategy  
 
 
Study Intervention: PureWick ™ System  
Potential adverse events:  
• Skin Injury  
• Skin Irritation  
• Allergic Reaction  PureWick ™ FEC is an 
external device placed 
between the separated 
gluteus and labia; it is in 
direct contact [CONTACT_690355]  • To avoid potential skin 
injury, never push or 
pull the PureWick™  
Female External Catheter against the skin 
during placement or 
removal.  
• Assess local area before 
device application/after 
device removal and 
periodically throughout 
use. 
• To monitor skin 
irritation, daily skin 
assessment will be 
performed using the 
Draize scale.   
• To avoid allergic 
reactions, study is using 
Non-latex PureWick ™ 
FEC  
Potential adverse events:  
• Allergic Reactions  
• Choking  
• Strangulation  
• Electrical Shock  
• Injury from Explosion  
• Chemical Burns  
  The PureWick ™ Urine 
Collection System is to be 
used with PureWick™  
External Catheters which are intended for non-
invasive urine output 
management.  •  Discontinue use if an 
allergic reaction occurs. 
Not recommended for 
users who are 
experiencing skin 
irritation or skin 
breakdown in device 
contact [CONTACT_95557].  
• Keep small device parts, 
cords and tubing out of 
reach of children . 
• Always unplug 
PureWick ™ Urine 
Collection System 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 26 of 67 
 before cleaning or when 
not in use.  
• DO NOT IMMERSE 
THE PUREWICK ™ 
URINE COLLECTION 
SYSTEM IN WATER. 
As with most electrical 
devices, electrical parts 
in this system are 
electrically live even 
when the power is off. 
To reduce the risk of 
electric shock, if the 
PureWick ™ Urine 
Collection System falls 
into water, unplug 
immediately. DO NOT 
REACH INTO THE 
WATER TO RETRIEVE IT.  
•  Do not  use PureWick ™ 
Urine Collection System  in oxygen rich 
environments or in conjunction with 
flammable anesthetics.  
• For PW200: The battery 
cells used in this device 
may present a fire or 
chemical hazard. To 
minimize the risk of 
damaging the battery 
inside the PureWick ™ 
Urine Collection 
System, do not use the 
device outside the 
indicated operating 
temperature range of 
41°F -  104°F (5°C -  
40°C). The battery is 
not intended to be 
replaced; replacement 
could result in a hazard.  
Study Intervention: Hollister® Female Urinary Pouch External Collection Device  
Potential adverse events:  
• Irritation  
• Broken skin  
• Rash  
• Sever e Redness  
• Swelling  Hollister® Female Urinary 
Pouch External Collection 
Device  is a urinary 
collection pouch with a 
skin barrier suitable for 
frequent pouch changes or • To avoid potential 
adverse events, while 
using the Hollister® 
Female Urinary Pouch 
External Collection 
Device , it is advised 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 27 of 67 
 • Itching or pain in vulva /perineal area  
• Fever  
• Abnormal D ischarge  use on fragile skin.  It is in 
direct contact [CONTACT_690356].  the product should not 
reuse the pouch after use. Reprocessing, cleaning, disinfection, 
and sterilization  may 
comprise the product.  
• Urinary pouch should 
only be used under supervision of healthcare 
professional. 
• Urinary pouch should 
not be used on patients 
with any 
contraindications per 
IFU. 
Study Procedures  
Potential loss of confidentiality of 
information  Study data, including 
photographs when 
applicable,  will be 
collected in the home setting  and transferred to 
the inves tigational site for 
colle ction in the clinical 
database.   • Access controlled 
Secure File Transfer 
Protoc ol (SFTP)  
software will be used 
to transfer data to 
investigational site  
 
 
2.5.1 Benefit Assessment  
 
Potential benefits to participants using the PureWick ™ System  may include: 
• The PureWick ™ System can help make better sleep possible for women with 
incontinence and their caregivers.24  
• The PureWick ™ System may help reduce the need for multiple changes at 
night, or trips to the bathroom.  
• The PureWick ™ System is easy to set up, and the PureWick ™ Female 
External Catheter  can be placed in a few easy steps.   
• PureWick ™ FEC can decrease risk of moisture- associated skin damage 
compared to the use of absorbent products such as adult briefs, pads, or sheets.  
 
Other potential benefits of study participation include:   
• Participants r eceive enhanced follow up, including daily skin assessments and 
urine output management by a nurse.  
• Participants c ontribute to the process of generating clinical evidence for urine 
output management solution in the home setting.  
• Potential to benefit from future reimbursement  of the PureWick system .  
 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 28 of 67 
 2.5.2 Overall Benefit: Risk Conclusion  
 
Taking into consideration the measures to minimize risk to participants in this study, the 
potential risks identified in association with the PureWick ™ System  and the Hollister® 
Female Urinary Pouch External Collection Device are justified by [CONTACT_690357].  
 
3.0 OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primary   
To compare efficacy and safety of 
PureWick ™ System  and Hollister® Female 
Urinary Pouch External Collection Device • Efficacy – Daily capture rate via bed pad 
weights and captured volume. 
• Safety – Daily skin irritation score using 
the Draize Scale. 
 
Secondary   
To assess impact of PureWick ™ System and 
Hollister® Female Urinary Pouch External 
Collection Device  on Nocturnal Incontinence 
related Quality of Life . • Nocturia Quality of Life (N -QOL) score 
collected at baseline and every 2 weeks 
during treatment. 
• PROMIS Sleep Disturbance score collected at baseline and every 7 days during treatment.  
Tolerability – To assess the tolerance of PureWick ™ System  and Hollister® Female 
Urinary Pouch External Collection Device over the expected duration of use  Tolerability – Number of days of actual use of both devices & Discontinuation rate attributed to the device’s inconvenience or discomfort 
To assess participant device preference, comfort,  and ease of use of PureWick ™ 
System and Hollister® Female Urinary Pouch External Collection Device  
To assess participant  preference between the 
PureWick ™ System and Hollister® Female 
Urinary Pouch External Collection Device 
after study completion  • Overall comfort and ease of use scores on a 5-point Likert scale (brief questionnaire) 
collected at the end of each treatment phase.  
• Overall preference via end of study 
participant preference survey administered at study completion   
Tertiary/Exploratory   
N/A N/A 
 
  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936486] -market, m ulti-site, open -label, c rossover t rial, women with 
urinary i ncontinence requiring the use of diapers (changes complets  (Fr)) at night  will be 
1:1 randomized to a treatment sequence using two devices (PureWick™ System and 
Hollister® Female Urinary Pouch External Collection Device ) and followed for 
approximately [ADDRESS_936487] parti cipation is approximately 10 
weeks. Participant s will use the device assigned in treatment phase 1 overnight while 
sleepi[INVESTIGATOR_48908] 4 weeks (28 days) before transitioning to the second assigned device in 
treatment phase 2. There will be a minimum washout period of 2 weeks  (not to exceed 4 
weeks)  between treatment phases and a re-screening of eligibility criteria before the 
second phase. Participants assigned to both treatment arms will place and remove the FEC (female external catheter) or FUP (Female Urinary Pouch) after standardized teaching is completed on the first day of the treatment phase.
 
The primary objectives are to  evaluate safety (skin injury) and efficacy (capture rate ). 
Safety will be assessed using the Draize Scale and efficacy will be measured based on daily urine capture rate.  Nurse s will visit participants’ homes  daily to perform a skin 
assessment and collect  urine  measurements during the treatment phases. Participant s will 
be withdrawn from the treatment phase if grade 4 is achieved in any category  on the  
Draize skin irritation scale . 
The secondary objectives are to assess  quality of life, tolerability, preference, comfort and 
ease of use. Quality of life  will be measured using self -reported changes in quality of life 
via the validated Nocturia Quality of Life (N -QOL) and PROMIS Sleep Disturbance  
assessments. Preference, comfort and ease of use will be measured using subjective  
evaluation s of the therapy via participant  surveys . Tolerability will be measured by 
[CONTACT_690358], and discontinuation rate attributed to the device’s discomfort or inconvenience.  
  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 30 of 67 
  
4.2 Scientific Rationale for Study Design  
 
This study will assess the performance of and user experience with PureWick ™ System  in 
a home setting. The endpoints chosen for the study were selected based on peer-reviewed 
research and feedback from expert consultants, Centers for Medicare & Medicaid 
Services, applicable health authorities and urology key opi[INVESTIGATOR_46830]. 
 
To best mimic potential users of the PureWick ™ System, participants >18 years of age 
will be enrolled  with a target of at appro ximately  90% of participants >[ADDRESS_936488]- treatment scores.  
 The PureWick ™ System may provide improvements to urine output management, 
specifically in the home -setting. Additionally , the PureWick ™ At -Home study is required 
to provide the needed information to properly execute a future global randomized control 
trial ( RCT ) with confidence of success. 
 
 
4.[ADDRESS_936489] mimic potential users of the PureWick ™ System, participants >18 years of age will be 
enrolled. It is desired that at approximately 90% of participants are >65 years of age. This study 
will enroll approximately 30 participants . 
 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   [ADDRESS_936490] meet all of the 
following criteria:  
 
1. Adult Female Participant s >18 years of age at the time of signing the informed 
consent. 
2. Currently use diapers or equivalent at night for urine  capture (“Change complet” 
(FR))  
3. Willing to comply  with all study procedures in this protocol.  
4. Provision of signed and dated informed consent form.   
 
5.2 Exclusion Criteria  
 Participants are excluded from the study if any of the following criteria apply:  
1. Has frequent epi[INVESTIGATOR_690337] a fecal management system in place; or  
2. Has moderate to heavy menstruation and cannot use a tampon or menstrual cup; or 
3. Has Urinary tract, vaginal or other chronic infections, active genital herpes; or 
4. Has Urinary retention; or 
5. Is agitated, combative, and/or uncooperative and may remove the external catheter or pouch; or 
6. Has any wound, open lesion or irritation on the genitalia, perineum, or sacrum; or 
7. Has any pre-existing neurological, psychiatric, or other condition that would confound quality of life assessment or would make it difficult to self-report on quality -of-life questionnaires in the opi[INVESTIGATOR_871]; or 
8. Is known to be pregnant at time of enrollment (for women of childbearing age); or 
9. Any other condition that, in the opi[INVESTIGATOR_871], would preclude them from participating in the study. 
10. Is under supervision of a legally authorized representative.   
 
5.3 Lifestyle Considerations  
 
No restrictions are required.  
 
5.4 Screen Failures  
 
Screen failures are defined as participants who consent to participate in the clinical study but do not subsequently meet eligibility criteria  prior to treatment. Data collected for 
screen failures will include consent,  randomization , criteria leading to exclusion, and  AEs .  
 
Individuals who do not meet the criteria for participation in this study (screen failure) may be rescreened  if the exclusionary criteria are temporary in nature and may resolve over 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 32 of 67 
 time ( e.g., active infection, open wound, et c.). Rescreened participants will receive a new 
participant number.  
 
 
6.0 STUDY INTERVENTION( S) 
 
6.1 Investigational/Test Device  
 
The PureWick ™ System includes the PureWick ™ Female External Catheter and the 
PureWick ™ Urine Collection System. The PureWick ™ Female External Catheter 
(PureWick ™ FEC) is marketed in both the [LOCATION_002] and Europe. In the U.S. 
PureWick ™ FEC is  a Class I, 510(k) exempt device . In Europe, t he PureWick ™ FEC  is a 
Class I,  CE marked, non- sterile device.  
 
The PureWick ™ FEC is intended for non- invasive urine output management in female 
patients.  The PureWick ™ FEC ( Figure 1) is a flexible, contoured external catheter that is 
positioned against the area where urine exits the female body.  The PureWick ™ FEC will 
be connected to the PureWick ™ Urine Collection System (PU CS) via co nnector tubing.  
The PUCS  uses suction (not felt by [CONTACT_28024]) to pull voided urine through the device.  
Urine continues through vinyl tubing until it reaches a collection canister, away from the 
body. The PureWick ™ FEC and PUCS  will be used according to the IFU.  
  
6.2 Pre-placement Procedure  
 
Prior to placing the PureWick ™ FEC, perineal care should be performed,  and skin 
should be assessed for integrity. 
 
Figure 1:  PureWick ™ Female External Catheter  
 
 

Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 33 of 67 
 Figure 2:  PureWick ™ Urine Collection System  
 
 
All PureWick ™ FECs and PUCS  will be shipped directly to the study site from regular 
commercial stock.   Access to the devices will be limited to study staff and will only be 
used by [CONTACT_690359]. 
 
6.3 Control Device/Standard of Care 
 
The Hollister ® Female Urinary  Pouch External Collection Device will be use d as a 
comparator for this study. The urinary collection pouch with a skin barrier is suitable for non-ambulatory females with urinary incontinence. It is designed to be emptied and should be attached to a drainage bag. The FUP is m ade with hydrocolloid skin adhesive and 
polymer/copolymer plastics. 
 6.4 Pre-placement Procedure  
 
To prepare the skin prior to placing the Hollister ® FUP,  the genital area should be 
washed with a mild soap and water and pubic hair trimmed. After drying the area thoroughly, the skin that will be in contact [CONTACT_690360] a skin protective wipe if desired.  
  The pre-cut opening on the skin barrier can be modified  so that it will encompass the 
urinary and vaginal orifices by [CONTACT_690361].  
 
If desired, barrier paste may be placed on the edge of the skin barrier that will adhere to areas where the skin surface is creased or uneven  prior to placement. 
   

Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 34 of 67 
  
Figure 3: Hollister ® Female Urinary Pouch One-S ystem  and Bedside Drainage Bag  
 
 
All Hollister ® Female Urinary Pouch External Collection Devices  will be shipped directly 
to the study site from regular commercial stock.   Access to the devices will be limited to 
study staff and will only be used by [CONTACT_690362]. 
 
6.5 Ancillary Devices/Products  
 
• PureWick ™ replacement kit (PWKIT 03) ( US) and (PWKIT03 E) (EU)  
• Absorbent under- pads will be used to collect and measure urine leakage.   
• Medium/Large sealing plastic  bags 
• Medical triangular graduated cylinders, 1000mL  
• Commercially available scales will be used to weigh under -pads and mesh underwear.  
both before and after use to calculate urine capture rates . 
• Bedside urine collection bags to capture outputs from the Hollister FUP  
• Bedside urine bag holder 
• Mesh Underwear  
• PPE (gloves, chux) 
• Barrier Paste  
• Wipes  
• Micropore tape  
• Hair trimmers/clippers  
 
6.[ADDRESS_936491] device and comparator products shall be labeled in accordance with regulatory requirements, including the following statement, "CAUTION - Investigational Device. Limited by [CONTACT_4496] (or [LOCATION_002]) law to investigational use." for the products used in the US , and with the 
following statement “exclusively for clinical investigation ” for the devices  used in [LOCATION_009].   

Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936492] study outcomes, standardized instructional videos  will be used to train all participants on device use.  
 6.8 Randomization  
 
Subjects will be randomized 1:1 to t he two sequences  of treatment (using PureWick ™ 
FECs  in phase 1  and Hollister
® Female External Pouch in phase 2, or the reversed order ). 
This design allows the evaluation of elements such as the carryover effect, period effect, 
and sequence effect.  To begin treatment phase in either the U.S. or [LOCATION_009] , using a prepared 
randomization schedule  participants will be randomized 1:1 to use either PureWick ™ FEC 
in phase 1 and Hollister ® FUP in phase 2, or vice versa. Block r andomization will be 
carried out using a fixed block size and  stratified by [CONTACT_690363].  
 
6.8.1 Blinding/Masking  
 
Not applicable.  This is an open- label study.  
 
6.8.2  Procedures for Unblinding  
   
  Not applicable.  
 
 
7.0 STUDY PROCEDURES AND ASSESSMENTS  
 
Study procedures and their timing are summarized in the Schema (Section 1.2). Protocol waivers or exemptions are not allowed. Adherence to the study design requirements, including those specified in the SoA , is essential and required for study conduct. 
 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936493] details of all participants screened and to confirm eligibility or recor d reasons for 
screening failure, as applicable.  
 
7.2 Screening and Enrollment  
 
7.2.1 Informed Consent  
 
The Principal Investigator [INVESTIGATOR_690339], 
answer all the participant’s questions, and obtain written or electronic informed consent  
before the collection of any study data or performance of any study procedures in 
accordance with article 63 of the European Medical Device Regulations respectively CFR Parts 50 and 56 and any other applicable laws and regulations.  The original copy of the consent will be retained with the participant records and a copy will be provided to the participant.  
 
7.2.2 Eligibility  
 The participant’s eligibility (inclusion/exclusion criteria) for study participation will be confirmed by [CONTACT_978] [INVESTIGATOR_1461]  (via on site or virtual visit ( U.S. only) ) per 
investigational site policy) and  documented on the appropriate electronic case report form 
(eCRF). Participant baseline and demographic information, including, but not limited to 
age, sex assigned at birth, primary diagnosis, medical history , Katz ADL  Index  score and 
incontinence -specific information will be collected and recorded after informed consent 
is obtained prior to device use .  
 
Participants who fail to meet eligibility criteria due to an exclusionary criterion that is 
temporary in nature and may resolve over time ( e.g., active infection, open wound, etc.) 
can be res creened  at the PI’s discretion.  
 
7.2.3 Enrollment / Assignment of Participant Number  
 
Participants who sign an informed consent will be considered enrolled in this study.   
A unique identification number will be given to study participant s. Participant  numbers 
will be assigned in sequential order. The participant number will consist of six digits. The 
first three digits will designate the site number and the last three digits will designate the 
participant number in sequential order.  
 
7.2.[ADDRESS_936494] will 
be enclosed indicating which device to be used for each treatment phase. The 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936495] will be filed in the participant’s record to serve as documentation. Participant randomization numbers will be captured in EDC.  
7.2.[ADDRESS_936496] daily home visits  (either in person or virtually) .  
 
Nurse and participant will arrange the baseline visit.  Once a baseline visit has been 
scheduled, the site coordinator/Pharmacist will reach out to Marken and setup study 
device shipment from clinical site to the Participant’s home.  
 
7.2.[ADDRESS_936497] nighttime routine  (e.g., sleep position)  and visually assess for any 
existing signs of irritation in the perineal area , using the Draize Scale Skin Scoring system.
 
 
If Skin Score is Greater than 0 : 
1. Participant is not eligible to begin treatment on that day.  
2. Baseline visit can be rescheduled at the nurse’s  discretion within  2-4 weeks . 
3. If the skin score of 0 is not achieved within 4 weeks from the original baseline visit, the 
participant will not be eligible for treatment.  
4. Nurse will notify PI [INVESTIGATOR_690340] e CRF s. 
 If Skin Score is 0:  
1. Nurse will have  participant complete Baseline N -QOL & PROMIS Sleep Disturbance 
assessment.  
2. Nurse will confirm treatment assignment. 
3. Nurse will provide device and procedure training  via standardized product training 
video.  
4. Once training is completed, nurse will ensure the participant have all the supplies prepped for the first  night of device wear . 
5. Nurse will pre -weigh and document  weight of sealed bed pad in bag  
6. If assigned to PureWick ™ treatment phase, nurse will pre -weigh and document weight 
of canister  before use.  
7. If assigned to Hollister FUP  treatment phase, nurse will pre -weigh and document 
weight of the graduated cylinder. 
8. If applicable, nurse will  pre-weigh and  document weight of mesh underwear in bag .  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936498] placed the used night pads and 
mesh underwear (if applicable) in the ir respective labeled , pre-weigh ed sealed  bag upon 
completion of sleep.  
2. Nurse will weigh and document weight of  night pads and mesh underwear (if 
applicable) . 
3. The nurse will weigh and document the captured urine . 
• For PureWick ™ Treatment Phase t he captured urine volume in the PW  urine 
collection  canister will be weighed and documented. 
• For Hollister ® FUP  Treatment Phase t he captured urine volume in the bedside urine 
bag will be emptied into a  graduated cylinder, then weighed and documented. 
4. The nurse will note any signs of skin irritation or injury and document the Draize Scale score*  
5. If during the skin assessment a Draize score of [ADDRESS_936499] be recorded as an AE and will require participants to 
discontinue from the treatment phase; participant will immediately begin wash out period and complete N -QoL.  
6. Nurse will pre -weigh  and document weight of study supplies for next night use. 
7. The nurse will confirm the next day visit . 
 * For safety assessment, see section 7. 3 
 
7.2.8 Day 8 
1. Same procedures as days 2 -7. 
2. Participant to complete Day 8 PROMIS  Sleep Disturbance assessment.  
7.2.9 Day s 9-14 
1. Same procedures as days 2 -7. 
7.2.10 Day  15 
1. Same procedures as day s 2-7. 
2. Participant to complete 2 -week N-QOL assessment . 
3. Participant to complete Day 15 PROMIS Sleep Disturbance assessment.  
7.2.11 Days 16- 21 
1. Same procedures as days 2 -7. 
7.2.12 Day  22 
1. Same procedures as days 2 -7. 
2. Participant to complete Day 22 PROMIS Sleep Disturbance assessment.  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   [ADDRESS_936500] 24 hours after treatment phase completion or discharge from the study to the PI [INVESTIGATOR_149057]. Skin assessments will also be conducted 24 hours after the participant completes the treatment phase and/or the study.  
7.2.16 Days 29-42 (+14) Wash Out Period 
Parti cipant begins washout period of 2 weeks (not to exceed 4 weeks) between treatment 
phase 1 and treatment phase 2.  At the completion of washout, the nurse will perform a re-
screening of eligibility criteria before phase 2 treatment begins. 
 
7.2.17 Treatment Phase 2 
Same procedures as outline in sections 7.2 – 7.11. 
 
7.3 Safety Assessments 
 
7.3.1 Draize Scale  
 
For each daily  visit (described in 7.2-7.7), skin condition will be evaluated by [CONTACT_690364] (Table 1).  Skin assessments will also be conducted [ADDRESS_936501] be recorded as an AE and will require participants to 
discontinue from the treatment phase.  Any other score on the skin irritation scale in any 
category may be recorded as an AE  based on PI [INVESTIGATOR_119752] n. 
 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   [ADDRESS_936502] s a follow up visit with the participant, 
this can be conducted on site or virtually per investigational site policy . 
 However, if the AE is not resolved during the treatment phase(s) within [ADDRESS_936503] ID and the date when the pi[INVESTIGATOR_690341]. These photographs will be shared with the Principal Investigator / Sub-Investigator, the Sponsor, and the study staff only and will be used for the Principal Investigator / Sub-Investigator’s review and assessment of the skin reactions.  
 
Table 1:  Draize Scale for Skin Irritation  
Score  Erythema (redness)  Edema (swelling)  Bleeding  
0 None  None  None  
1a Very slight (barely 
perceptible) erythema  Very slight (barely 
perceptible) skin surface rise  Just a visible spot of red  
2a Well -defined erythema Well -defined skin surface rise 
(edges of area well -defined by 
[CONTACT_363681])  A drop of red blood 
3a Moderate erythema  Moderate skin surface rise  A continuing ooze of red 
blood  
4b Severe (beet red) or 
damage to skin (eschar 
formation)  Severe skin surface rise  Significant bleeding from 
the sight  
a = Represents irritation in any category and may require participant ’s removal from the study  based on PI 
[INVESTIGATOR_21781] . 
Note: a rating of 1-3 on the skin irritation scale in any category may be recorded as an AE based on PI 
[INVESTIGATOR_9106].  
 
b = A rating of [ADDRESS_936504] be recorded as AE and will require 
participant’s removal from the treatment phase and/or study. 
 
7.4 User Preference Questionnaire 
Prior to each treatment phase completion , the participant will be asked to complete a short 
questionnaire on their experience with the PureWick™ System  or the Hollister ® FUP. The 
questionnaire is designed to assess the following: 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 41 of 67 
 • Comfort with PureWick ™ FEC/PureWick ™ Urine Collection System or  the 
Hollister® Female Urinary Pouch External Collection Device  
• Ease of use in placing and removing the PureWick™ FEC  and the Hollister® 
Female Urinary Pouch External Collection Device  
After completing both treatment phases  for the study, t he participant will complete the 
preference questions on their experience with the PureWick™ System and  the Hollister® FUP.  
The survey is designed to assess the following:  
• The participants preferred  device a fter using both the PureWick™ 
FEC/PureWick ™ Urine Collection System and the Hollister® Female Urinary 
Pouch External Collection Device .  
 
 7.[ADDRESS_936505] 24 hours after discharge from the study to the PI [INVESTIGATOR_10157] . 
 
7.6 Replacement of Participants  
A participant that discontinues from the study will be replaced when feasible.    8.0 PARTICIPANT DISCONTINUATION/WITHDRAWAL  
   
8.1 Discontinuation/Withdrawal  
 
• A participant may withdraw from the study at any time at his/her own request or may be withdrawn at any time at the discretion of the investigator or sponsor for safety, 
behavioral, compliance, or administrative reasons. This is expected to be uncommon. 
• At the time of discontinuing from the study, no further assessments will be performed.  
• If the participant withdraws consent for disclosure of future information, the sponsor may retain and continue to use any data collected before such a withdrawal of consent.  
• Participants who withdraw or discontinue the study early may be replaced.  
 
8.[ADDRESS_936506] be taken if a participant fails to keep the visit schedule  or is 
unable to be contact[INVESTIGATOR_530]:  
 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 42 of 67 
 • The site  and nurse  must attempt to contact [CONTACT_690365]/or should conti nue in the study. 
• Before a participant is deemed lost to follow up, the investigator or designee must 
make every effort to rega in contact [CONTACT_6635].  Where possible, 3 
telephone calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods. These contact [CONTACT_13140]’s study re cord.  
• Should the participant continue to be unreachable, she will be considered to have withdrawn from the study. 
 9.0 ADVERSE EVENTS AND DEVICE DEFICIENCIES  
 
9.1 Definitions of Events  
 
9.1.1 Adverse Events (AEs)  
 
An AE is defined as any untoward medical occurrence, unintended disease or  
injury, or untoward clinical signs (including abnormal laboratory findings) in 
participants, users or other persons, whether or not related to the  investigational device 
and whether anticipated or unanticipated ( ISO14155:2020) .  This definition includes 
events related to the investigational device , the comparator or the procedures involved. 
 Pre-existing conditions should be considered as part of the participant’s medical history 
and should not be reported as an AE unless there is a substantial increase in severity or 
frequency of the condition, which has not been attributed to natural history. Likewise, 
planned hospi[INVESTIGATOR_690342]/or hospi[INVESTIGATOR_690343].  
Exacerbation of an existing condition should be reported as an AE if the event meets the protocol definition of an AE.  The clinical course of the event will be followed according to accepted standards of 
medical practice until the event resolves, stabilizes, or in the opi[INVESTIGATOR_689], 
is no longer considered clinically significant.  The Investigator must supply the Sponsor 
with information concerning the follow up and/or resolution of the AE.  
 
9.1.2 Serious Adverse Events (SAEs)  
 
A serious adverse event is defined by [CONTACT_5891] [ZIP_CODE] and/or 21 CFR 803.3 as an adverse event that led to :  
a. Death,  
b. Serious deterioration in the health of the participant, users, or other persons as 
defined by [CONTACT_10980]:  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 43 of 67 
 • a life -threatening illness or injury, or  
• a permanent impairment of a body structure or a body function including 
chronic diseases, or  
• in-patient or prolonged hospi[INVESTIGATOR_059], or  
• medical or surgical intervention to prevent  life-threatening illness or injury, 
or permanent impairment to a body structure or a body function, 
 
c. Fetal distress, fetal death, a congenital abnormality, or birth defect including 
physical or mental impairment.  
 
NOTE: Planned hospi[INVESTIGATOR_5315] a preexisting condition, or a procedure required by [CONTACT_690366], is not considered an SAE.  
 
9.1.[ADDRESS_936507] (ADE) / Serious Adverse Device Effect (SADE)  
 
An adverse device effect is defined as any adverse event that is considered to be related to the use of an investigational medical device. This definition includes any event resulting from insufficiencies or inadequacies in the instructions for use, deployment, implantation, or operation or any malfunction of the investigational device and  includes 
any event that is a result of a user error , intentional misuse of the investigational medical 
device and/or comparator if the comparator is a medical device.  
 
A serious adverse device effect (SADE) is defined as an ADE that has resulted in any of 
the consequences characteristic of an SAE.  An anticipated serious adverse device effect 
(ASADE) is an effect which by [CONTACT_5942], incidence, severity or outcome has been 
identified in the risk assessment. 
 
9.1.4 Unanticipated (Serious) Adverse Device Effect (UADE/[LOCATION_003]DE)  
 
An unanticipated (serious) adverse device effect (UADE/[LOCATION_003]DE) is any (serious)  
adverse device effect on health or safety or any life -threatening problem or death  
caused by, or associated with, an  investigational device , which by [CONTACT_5942], incidence,  
severity, or outcome has not been identified in the current instructions for use and/or 
current version of the risk analysis report, or any other unanticipated serious problem associated with a device that relates to the rights, safety or welfare of participants.  
Anticipated serious adverse device effect (ASADE) is an effect which by [CONTACT_5942], 
incidence, severity or outcome has been identified in the risk assessment. 
 A sponsor shall immediately conduct an evaluation of any unanticipated adverse device effect.  
 
UADEs/[LOCATION_003]DEs will be reported to FDA as required by 21 CFR Part 812 and ISO 
[ZIP_CODE]:2020 and will be reported to the appropriate governing body per ISO [ZIP_CODE]:2020. 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 44 of 67 
  
9.2 Severity of Adverse Events  
 
Each AE shall be assessed for its severity, or the intensity of an event, experienced by [CONTACT_690367]. 
 
Severity Rating  Description  
Mild  Event, s igns, or symptoms that do not interfere with the participant ’s 
daily activity, are usually considered self- limiting, can be treated 
with non-prescription type medications, and do not require medical 
intervention  
Moderate  Event may interfere or cause low level inconvenience with the 
participant ’s daily activity. Requires medical intervention and/or 
treatment ; however, unlikely to require hospi[INVESTIGATOR_690344] -threatening in nature  
Severe  Event may cause significant discomfort to the participant  and/or 
interferes with the participant ’s daily activity. Requires medical 
intervention and/or treatment to preclude a permanent impairment; 
may be life threatening and /or require hospi[INVESTIGATOR_059]  
  
9.3 Relationship of Adverse Event to Device(s)/Procedure  
 
Each AE will be assessed for its relationship to the investigational device or procedure according to the following guidelines. 
 
A.  Assess each AE for its relationship to the device or procedure. 
 
• Device Related: This category should be restricted to AEs directly attributable to 
the PureWick ™ System  and Hollister® Female Urinary Pouch External 
Collection Device  during the urine capture assessments.  
 
• Procedure:  A procedure includes any study-related activity performed during the 
set-up or application of the PureWick™ System and Hollister® Female Urinary 
Pouch External Collection Device and/or urine capture assessment procedure.  
 
B.  To assess the causality, clinical judgement should be used and the relevant study 
documentation, such as the study protocol should be consulted. The presence of 
confounding factors, such as concomitant medication/treatment, underlying diseases, other concurrent illness or risk factors should also be considered. The above considerations apply also to the serious adverse events occurring in the comparison group.  
Each SAE will be classified according to four different levels of causality:  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 45 of 67 
 1. Not R elated  
2. Possible  
3. Probable 
4. Causal R elationship  
 
Relatedness  Description  
Not Related  Relationship to the device, comparator or procedures can be 
excluded when:  
• the event has no temporal relationship with the use of the 
investigational device, or the procedures related to application of the investigational device;  
• the serious adverse event does not follow a known response pattern to the medical device (if the response pattern is previously known) and is biologically implausible;  
• the discontinuation of medical device application or the 
reduction of the level of activation/exposure - when 
clinically feasible - and reintroduction of its use (or 
increase of the level of activation/exposure), do not impact on the serious adverse event;  
• the event involves a body-site or an organ that cannot be affected by [CONTACT_41491];  
• the serious adverse event can be attributed to another cause (e.g. an underlying or concurrent illness/ clinical condition, an effect of another device, drug, treatment or other risk factors);  
• the event does not depend on a false result given by [CONTACT_75698], when applicable;  
 
In order to establish the non- relatedness, not all the criteria 
listed above might be met at the same time, depending on the 
type of device/procedures and the serious adverse event. 
 
Possible The relationship with the use of the investigational device or 
comparator, or the relationship with procedures, is weak but 
cannot be ruled out completely. Alternative causes are also possible (e.g. an underlying or concurrent illness/ clinical condition or/and an effect of another device, drug or treatment). Cases where relatedness cannot be assessed, or no information has been obtained should also be classified as 
possible.  
Probable The relationship with the use of the investigational device or 
comparator, or the relationship with procedures, seems 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 46 of 67 
 relevant and/or the event cannot be reasonably explained by 
[CONTACT_5748].  
 
Causal  
Relationship  the serious adverse event is associated with the investigational 
device, comparator or with procedures beyond reasonable 
doubt when:  
• the event is a known side effect of the product category the device belongs to or of similar devices and procedures;  
• the event has a temporal relationship with investigational 
device use/application or procedures;  
• the event involves a body -site or organ that  
o the investigational device or procedures are applied 
to;  
o the investigational device or procedures have an effect on;  
• the serious adverse event follows a known response pattern to the medical device (if the response pattern is previously known);  
• the discontinuation of medical device application (or reduction of the level of activation/exposure) and reintroduction of its use (or increase of the level of activation/exposure), impact on the serious adverse event (when clinically feasible);  
• other possible causes (e.g. an underlying or concurrent illness/ clinical condition or/and an effect of another device, drug or treatment) have been adequately ruled out;  
• harm to the subject is due to error in use;  
 
the event depends on a false result given by [CONTACT_690368]; In order to establish the relatedness, not all the criteria listed above might 
be met at the same time, depending on the type of device/procedures a nd the serious adverse event.  
 
 
9.4 Reporting of Events  
 For all adverse events, all sections of the appropriate electronic Case Report Form ( eCRF) must 
be completed  including AE start and end date, outcome of AE, severity, seriousness, relationship 
to device and relationship to the procedure . All AEs  shall be  promptly reported to the Sponsor . 
 
For European site(s):
 
 
• All SAEs, SADEs, UADEs/[LOCATION_003]DEs, and Serious Health Threats must be 
reported to the Sponsor  via completion of the appropriate eCRF  no later than 3 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 47 of 67 
 calendar days of the site/investigator becoming aware of the event. If the study 
team is unable to access the electronic data capture system, the event may be 
reported to the Sponsor by [CONTACT_110191] [EMAIL_13153] . 
 
• De-identified copi[INVESTIGATOR_690345] 72 hours of knowledge, as appropriate.  
 
For U.S. site(s):  
• All SAEs, SADEs, UADEs/[LOCATION_003]DEs, and Serious Health Threats must be 
reported to the Sponsor via completion of the appropriate eCRF within  1 working 
day of the site/investigator becoming aware of the event. If the study team is 
unable to access the electronic data capture system, the event may be reported to 
the Sponsor by [CONTACT_110191] [EMAIL_13153] .   
 
• De-identified copi[INVESTIGATOR_690345] 72 hours of knowledge, as appropriate.  
 
In the US, i t is the responsibility of the Investigator  to report adverse events to individual 
Institutional Review Boards (IRBs)  and/or regulatory authorities  according to the local 
regulations . 
 
In Europe , it is the responsibility of the S ponsor to r eport adverse events to individual 
Ethics Committees (ECs) and/or regulatory authorities  according to the local regulations  
in each participating country. 
• For the purpose of this guidance and based on the definitions above, the following 
events are considered sponsor reportable events in accordance with MDR Art. 80(2): 
 
a) any serious adverse event that has a causal relationship with the investigational device, the comparator or the investigation procedure or where such causal relationship is reasonably possible;
 
b) any device deficiency that might have led to a serious adverse event if appropriate action had not been taken, intervention had not occurred, or circumstances had been less fortunate; 
 
c) any new findings in relation to any event referred to in points a) and b).  
 
9.[ADDRESS_936508] or possibility of multiple deaths occurring at s hort intervals  
(ISO14155:2020)  
 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936509].  Device deficiencies also include use 
errors and inadequate labeling.   This applies to: devices used to treat the participant , or devices in 
which the package was opened, but the device was not used for treatment, or devices with which treatment was attempted, but the device did not remain through the entire study procedure/ period.  
 
All device deficiencies  will be recorded  on the appropriate Case Report Form and will be 
promptly reported to the Sponsor. All sections of the appropriate eCRF must be completed including date of deficiency, time of deficiency, device identifiers (i.e. lot number, serial number) . The  device(s) should be returned to the Sponsor as outlined in the site ’s regulatory 
binder. 
 
If the device deficiency was associated with an AE, the reporting provisions for AEs,  
ADEs, SAEs, SADEs and UADEs/[LOCATION_003]DEs apply.  If the device deficiency was not associated 
with an AE, an assessment of w hether the device deficiency could have led to a SADE if suitable 
action had not been taken, if intervention had not been made or if circumstances had been less fortunate should be reported.  
 
Reported deficiencies will be investigated and reported under 21 CFR part 803 Medical Device Reporting and ISO [ZIP_CODE]:[ADDRESS_936510] a thorough investigation. 
 
It is the responsibility of the Investigator  for the U.S. and Sponsor for [LOCATION_009]  to notify the 
IRB/EC of such device deficiencies  in accordance with the IRB/EC and/or the Competent 
Authority’s local regulations. 
 
 
10.[ADDRESS_936511] important 
endpoints including primary and key s econdary endpoints. 
 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 49 of 67 
 10.1 Overview of Stu dy Design  
 
This is a prospective, open- label , 2 by 2, c rossover t rial to evaluate the safety , efficacy, 
and patient quality of life of PureWick ™ System in comparison with Hollister ® Female 
Urinary  Pouch. Par ticipants  are randomized 1:1 to use PureWick ™ System  in phase 1 
and Hollister ® Female External Pouch  in phase 2, or to use Hollister ® Female Urinary  
Pouch in phase 1 and PureWick ™ System  in phase 2. Each phase last s 4 weeks, with a 2-
4 week  washout period between phase 1 and phase 2. Capture rates  and Draize Scale are 
assessed dail y during both phases. Q uality of life is assessed at baseline and every 14 
days during phases 1 and 2. U ser preference questionnaire s are completed at the 
completion  of each treatment phase. The primary efficacy endpoint is the mean of  daily 
capture rate. The primary safety endpoint is the mean of daily assessment s of Draize 
Scale.  
 
10.2 Sample Size Considerations  
 
Approximately 30 participants will be enrolled . The  sample size is planned  based on 
operational and practical  considerations  and is adequate for the purpose of this pi[INVESTIGATOR_11480]. 
 
10.3 Analysis Population  
 
The following populations are defined:  
 
Population  Description  
Enrolled  Subjects  who signed  ICF. 
Intent -to-Treat  (ITT)  Subjec ts who signed ICF and randomized to a treatment 
sequence.  
As-Treated (AT)  ITT subjects , grouped by [CONTACT_690369], if different 
from planned treatment sequence.  
Per-Protocol  (PP) ITT subjects without major protocol deviation.  
 ITT population will be used for the analyses of endpoints. Sensitivity analyses may be carried out using AT or PP population.  
 
10.[ADDRESS_936512] to follow -up or 
withdrawal of consent. Reason for missing endpoints will be reported. For the 
primary efficacy endpoint, i f capture rate assessments are missing for part of a 
treatment phase, derivation of the primary efficacy endpoint  will be based on 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936513] is planned for this pi[INVESTIGATOR_799]. P values and confidence 
intervals  may be provided for exploratory purposes and are unadjusted for 
multiplicity.  
 
10.5 Primary Endpoint(s)  
 
10.5.1 Primary Efficacy  Endpoint  
 
Capture  rates is  evaluated daily during participant  phase  1 and phase 2. D aily capture rate is 
defined as:  
 
captured  urine  weight / (captured  urine  weight + leaked urine weight ) 
 The pri mary efficacy endpoint is  derived by [CONTACT_690370]. Descriptive statistics of the primary effic acy endpoint, including mean, standard 
deviation, median, and range will be provided by [CONTACT_3148]. The paired difference in mean 
daily capture rate between treatment s will be provided. 
 
 
10.5.[ADDRESS_936514] deviation, median, and range will be provided by [CONTACT_3148] . Paired 
difference in mean daily Draize Scale between treatment will be provided.  
 
10.6 Secondary Endpoint(s)  
10.6.1 Questionnaire Nocturia Quality of Life  (N-QoL)  
 
The questionnaire consists of [ADDRESS_936515] of nocturia on quality of life) . Descriptive statistics will be 
provided by [CONTACT_690371] . Mixed effect linear regression model may be used, with 
treatment and sequence as the fixed effect, and participant  as the random effect.  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 51 of 67 
  
10.6.2 Questionnaire PROMIS Sleep Disturbance  
 
Items in the questionnaire will be summarized both as categorical variable (using frequency count and percentage) and as continuous variables (using mean, standard deviation, median, and  range ) by [CONTACT_3148].  
 
10.6.3 Tolerability  - Number of days of actual use  
 
Number of days of actual use  will be summarized using descriptive statistics by 
[CONTACT_3148]. Paired difference between treatment will be provided. 
 
10.6.4 Tolerability -  Discontinuation rate due to device discomfort or inconvenience 
 
Rate of not completing a treatment phase due to device discomfort or inconvenience will be summarized using descriptive statistics.  
  
10.6.5 Comfort, E ase of U se and C onfidence  
 
Items in the questionnaire will be summarized both as categorical variable (using 
frequency cou nt and percentage) and as continuous variables  (using mean, standard 
deviation, median, and  range ) by [CONTACT_3148].  
 
10.7 Tertiary/Exploratory Endpoint(s)  
Not applicable.  
 10.[ADDRESS_936516] MAINTENANCE  
 
11.1 Case Report Forms  
The Investigator is responsible for ensuring the completeness and accuracy of all study 
documentation. 
 
All required clinical data will be collected/documented in sponsor -provided  web -based  
electronic Case Report Forms ( eCRFs). The eCRFs are designed to accommodate the 
specific elements of this clinical investigation and it is the responsibility of the Investigator to confirm that the data is completely and accurately entered in the appropriate sections of 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 52 of 67 
 the eCRF. Data reported on the eCRFs shall be derived from, and be consistent with, source 
documents and will be approved by [CONTACT_737]. An audit trail of changes or corrections 
to eCRFs will be maintained. Discrepancies between the source documents and the eCRFs 
shall be explained in writing. FDA 21 CFR 11 and ISO [ZIP_CODE]:2020, 7.8.3 are  followed as 
well as other applicable legislation on the handling of electronic data. Modification of the CRFs will only be  made if deemed necessary by [CONTACT_1052]/or the appropriate 
regulatory body.  
 
Site numbers and Participant numbers will be used to track participant information throughout the study.  Participant personal information will be de -identified.  
 
11.[ADDRESS_936517] be recorded and maintained in the study file of each enrolled participant.  
 
11.3 Data Management  
Data management is the responsibility of the Sponsor.  Data from completed CRFs will be 
managed in a secured, controlled database. A Data Management Plan (DMP) will be 
developed that outlines the procedures used for database design  and testing, database 
security, data review, database cleaning and issuing/resolving data queries. Procedures for 
validations , database finalization  and data storage will also be contained within the DMP. 
Observation data will be collected prospectively at the time of each urine output monitoring event.  As such, any missing data or inconsistent data cannot be retrieved from an alternate source. Particular care must be taken to ensure that all data are recorded in a clear and complete manner.   
 
11.[ADDRESS_936518] Retention  
       For United State s: The Investigator shall retain all study records for a minimum of two (2)  
years after the later of the following two dates: the date on which the study is 
terminated /completed or  the date that the records are no longer required for purposes of 
supporting a pre -market  approval application or a notice of completion of a product 
development protocol ( 21 CFR Part 812.140). The data for some of these records may be 
available in computerized form but the final responsibility for maintaining study records 
remains with the Investigator.  
 
For European sites: Documentation shall be kept for a period of at least [ADDRESS_936519] 10 years after the las t device has been placed on 
the market.  
 
The Investigator may withdraw from the responsibility to maintain records for the period  
required by [CONTACT_690372]. Notice of a transfer shall be given to the Sponsor and  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 53 of 67 
 FDA, if applicable, not later than ten (10) working days after the transfer occurs.  
 
 
12.[ADDRESS_936520] 
obtained written IRB/EC approval (as required) for participation in this study, who have completed all required study documentation, and who have been qualified by [CONTACT_941] S ponsor.  
Investigators must maintain control over all study products, and ensure they are used in accordance with this protocol.  Failure to do so may result in the Sponsor suspending or terminating the study at the Investigator’s site.  
  
The Investigator will ensure that study products are only dispensed to participants (or used for specimens) properly enrolled in the study. The Investigator must maintain records of receipt, disposition, return and/or destruction of all study products. All  investigational study 
products released to the site must be accounted for at the unit level prior to study close out, regardless of disposition.  The Sponsor -Monitor will regularly review all records regarding 
study product accountability.  
 
The Sponsor will maintain records that document the shipment, receipt, disposition, return and/or destruction of study products. A Study Supply Plan will be developed that contains study material traceability information  and labeling requirements . Study product handling 
and accountability procedures will be outlined in the Clinical Monitoring Plan (CMP).  
 
12.[ADDRESS_936521] operating procedures and the study-  
       specific Monitoring Plan.   
 
      Prior to study start, a s ite initiation visit (SIV) will be conducted to review with the  
      Investigator(s) and staff the provisions and proper conduct of this study. This visit will  
      include a detailed review of this protocol, verification that all necessary documents are on    
      file at the investigational site and confirmation of IRB/EC approvals.   
 
      During the study, routine monitoring visits (RMVs) will be conducted to assure the site  
      continues to adhere to the protocol, the investigator agreement, and regulations regarding  
      conduct of clinical studies.  The Sponsor -Monitor will confirm that the ICF to be used is the  
      version approved by [CONTACT_1201]/EC, confirm the applicable national privacy laws have been  
      followed, verify that all necessary documents are on file at the investigational site and        confirm that there are provisions to continue and maintain all documents and records  
      throughout the study as required by [CONTACT_5279]. These monitoring visits will      
      assess continued protocol compliance, adequate participant enrollment, accurate data       
      reporting, monitoring of participant safety through identification and/or review of any    
      device- related  AEs, UADEs, or SAEs, device accountability, continued maintenance and  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 54 of 67 
      calibration of study- specific equipment (if applicable), and continued IRB/EC acceptance of  
     the study. 
 
    At the completion of the study, the Sponsor -Monitor will conduct a final close -out visit or  
    COV. The purpose of this visit may include but is not limited to collecting all outstanding  
    study data documents, confirming that the Investigator’s files are accurate and complete,  
    reviewing the record retention requirements with the Investigator, providing for the return of  
    unused devices to the Sponsor, reviewing records which account for device shipments and  
    ensuring that all applicable requirements for closure of the study are met.  
 
12.[ADDRESS_936522] agree to the inspection of all study related records and give the  
    auditor/inspector direct access to source documents for verification of data on CRFs.  The  
    participant’s anonymity must be ensured, and data checked during the audit must remain     confidential.  
 
    As soon as the Investigator is aware of an upcoming inspection/audit by [CONTACT_690373], he/she will promptly inform the Sponsor.  As agreed with the Investigator,  
    Sponsor personnel may be present at the site during the inspection. 
 
12.[ADDRESS_936523] the life or physical well -being of a participant, protocol    
     deviations are not permitted.  The Sponsor and the investigational site’s IRB/EC must be       notified immediately if an emergency situation arises in which the safety of a participant may  
     require immediate intervention different than that defined in the protocol.  This must be  
     followed by [CONTACT_270898], within  
     five (5) working days from the date of the emergency action in accordance with the governing  
     IRB/EC’s requirement.   
 
     It is the Investigator’s responsibility to ensure that there are no deviations from the  Protocol.   
     Except in an emergency, when a protocol deviation is planned or anticipated, the Sponsor  
     should be contact[CONTACT_291444].  Any and all deviations must be recorded on the appropriate  
     CRF regardless of whether medically justifiable or sponsor approved.  Upon evaluation by [CONTACT_690374], actions may be required to prevent additional deviations, such as retraining of the  
     site, implementation of additional site procedures, and more frequent monitoring.  If these  
     steps fail, more serious measures, up to and including termination of enrollment at the site.  
 
  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936524]  
appropriate research experience and infrastructure to ensure adherence to this protocol  
and enrollment of sufficient numbers of evaluable participants. The curriculum vitae (CV) of 
the Investigator(s), Sub- Investigator(s) and Study Coordinator(s) will be maintained in the 
Sponsor’s files as documentation of qualification by [CONTACT_690375].  
 
The Principal Investigator [INVESTIGATOR_690346], agreeing to comply with all applicable regulations and the requirements of this study as  
per the clinical study agreement .  Federal databases will be searched to ensure that the 
Investigator(s) and/or the site are not prohibited from engaging in federally sponsored clinical research.   
 
Any site that is deactivated prior to initial enrollment, either by [CONTACT_690376], may be replaced.  
 
13.[ADDRESS_936525] training will be  
       provided by [CONTACT_690377]. Additional study        staff (e.g., Sub- Investigator(s)) will also require device training provided from the Sponsor  
       or proctoring by [CONTACT_978]. All training will be documented and filed at the investigational site  
      and with the Sponsor. 
 
13.3 Required Documents  
      An Investigator may not screen or enroll participants until authorized to do so by [CONTACT_690378]. At a minimum, the following documentation should be received by [CONTACT_690379]: 
• Fully executed Non- disclosure Agreement (NDA) between PI/site and Sponsor;  
• CVs, signed and dated within 2 years of study start for the PI [INVESTIGATOR_34511]-Investigator(s);  
• CVs for Study Coordinator(s);  
• Signed CSA by [CONTACT_976]/site (or designee);  
• Signed Investigator Agreement Page by [CONTACT_976] [INVESTIGATOR_34511]- Investigator(s);  
• Signed Financial Disclosure Statement by [CONTACT_976] [INVESTIGATOR_34511]- Investigator(s);  
• Completed and Signed Training Log by [CONTACT_976] [INVESTIGATOR_34511]- Investigator(s);  
• Study Personnel Identification list;  
• Written approval from the IRB/EC of both the protocol and ICF, and any other   
applicable protocol specific material; and  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 56 of 67 
 • IRB/EC Membership List, Assurance of Compliance Form  (for US only) , or 
equivalent.  
 
13.4 Publication Policy  
The sponsor believes that results of applicable clinical studies should be published in peer -
reviewed literature in a timely, accurate, complete and balanced manner, regardless of study 
outcomes, whenever possible.  As such, at the conclusion of this study, an article may be 
prepared for publication in a reputable scientific journal.  Formal presentation(s) or 
publication(s) of data collected from this study will be considered as a joint publication by 
[CONTACT_093](s) and the appropriate personnel of the Sponsor. Authorship will be based on generally accepted criteria of the ICMJE (International Committee of Medical Journal Editors) and determined by [CONTACT_11402].  
 
The publication of the principal results from any single -center experience within the study is 
not allowed until the preparation and publication of the multicenter results. Exceptions to this rule require the prior approval of the Sponsor. The analysis of other pre -specified and 
non-pre-specified endpoints will be performed by [CONTACT_4885]. Such 
analyses, as well as other proposed investigations or manuscripts will require the approval of the Sponsor. 
 
13.[ADDRESS_936526] of 
2007 (FDAAA), the Sponsor will register this study studies and disclose study results in a 
publicly accessible database (i.e., ClinicalTrials.gov).  This study will be regis tered no later 
than [ADDRESS_936527] of the clinical investigation and the 
results entered at  completion of the clinical investigation  (ISO14155:2020) . 
 
13.6 Termination of Study  
The Sponsor reserves the right to suspend enrollment or terminate the study at any time  
for any reason.  The Sponsor may suspend enrollment or terminate the study at a  
specific investigational site for reasons including, but not limited to, inadequate data  
collection, low participant enrollment rate, achievement of the total enrollment, conditions 
imposed by [CONTACT_3488]/EC and/or non- compliance with this protocol or other clinical 
research requirements. Written notice will be submitted to the Investiga tor in advance of 
such termination.  
 
In the event of study suspension or termination, the Sponsor will send a report outlining  
the circumstances to the IRB/EC, and all Investigators and Regulatory Authorities as  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 57 of 67 
 required by [CONTACT_5151]. If the study w as terminated, resumption would be done according to 
21 CFR Part 812.  
 
14.0 ETHICAL AND REGULATORY CONSIDERATIONS  
 
14.1 IRB/EC Approval  
Investigators or designees must submit the study protocol, Informed Consent Form (if 
applicable), and all other locally required documentation to an appropriate IRB/EC and obtain study- specific written approval (favorable opi[INVESTIGATOR_1649]) before being allowed to 
participate in the study. Before commencement of the study, the Investigator or designee must provide the Sponsor with written documentation of such approval.  If applicable, t he 
IRB/EC must give written renewal of the original approval at least annually to continue the study. A copy of the written renewal must be provided to the Sponsor. 
 
The IRB/EC will be notified of any amendments to the protocol, as well as possible associated information and consent form changes, where applicable, and written approval (favorable opi[INVESTIGATOR_1649]) will be obtained prior to implementation, as applicable. 
The Investigator or designee is responsible for fulfilling any conditions of approval imposed 
by [CONTACT_1201]/EC, such as regular safety reporting, study timing, etc.  The Investigator or 
designee will provide the Sponsor with copi[INVESTIGATOR_690347].  
 
14.2 Informed Consent and Confidentiality  
 
Prior to any study procedure, the Investigator (or designee) must explain to each participant in layman’s terms, the nature of the study, its purpose, expected duration, and the risks  and 
benefits of study participation. Also, participant  will be informed of uses and disclosures of 
their medical information for research purposes, and their rights to access  information about 
them. All applicable national privacy laws (e.g., HIPAA requirements  in the U.S., General 
Data Protection Regulation [ GDPR] requirements in the EU ) will be followed in this study. 
The participants  must be informed of their right to  withdraw from the study at any time and 
for any reason without sanction, penalty, or loss of benefits to which they are otherwise entitled, and that  withdrawal from the study will not jeopardize their future medical care. 
Participants  will be informed of their right to new  information and/or findings relating to the 
clinical study, and the process by [CONTACT_690380]. After this 
explanation, given sufficient time to decide  whether to participate, before any study 
procedure is conducted, and before entering the  study, the participant  must voluntarily 
provide consent in accordance with 21 CFR Parts 50 and 56 and ISO [ZIP_CODE]:2020(E). The participant  will receive a copy of his/her signed ICF.  
  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   [ADDRESS_936528] by [CONTACT_737], study staff, and 
the Sponsor.  Participant confidentiality and anonymity will be maintained by [CONTACT_690381], documentation, or clinical samples submitte d to the Sponsor. 
 
Any data collected meeting the definition of protected/confidential health information or 
personal identifying information will be collected and maintained using the designated 
authorizations and following privacy procedures as specified in the applicable health authority regulations.   
 
The Sponsor -Monitor, authorized representatives of the sponsor, and/or applicable Health 
Authorities may inspect all documents and records required to be maintained by [CONTACT_737].  The Investigator/Site will permit access to such records.  
 
14.4 Regulatory Status  
       The PureWick ™ System, comprised of the PureWick ™ Female External Catheter  and the  
        PureWick ™ Urine Collection System,  is a Class I, 510(k) exempt device currently  
       marketed in the [LOCATION_002]  and will be evaluated for its approved indication. The  
       investigational  device is CE marked and will be studied in a post -market fashion in Europe.  
 
The Sponsor has determined this to be a non- significant risk  study. Institutional Review 
Board (IRB) or Ethics Committee (EC) submission of this study plan along with IRB/EC 
study approval or waiver is required. The study will comply with the abbreviated IDE requirements under CFR 812.2 (b).  
  
14.5 Statement of Compliance  
       This clinical investigation will be conducted in compliance with the investigator agreement,  
       protocol and f ollowing regulatory requirements:  
• 21 CFR 50, 54, 56 and 812;  
• 21 CFR 812 (Good Clinical Practice);  
• ISO14155: 2020 (Good Clinical Practice);  
• EU MDR (Council Regulation 2017/745 of 5 April 2017)  
• MDCG guidelines  
• Ethical principles that have their origin in the Declaration of Helsinki; and  
• Applicable sections of the national laws and regulations. 
 
The clinical investigation will not commence at a clinical site until approval (favorable 
opi[INVESTIGATOR_1649]) from the respective IRB/EC has been received. All additional requirements 
imposed by [CONTACT_1201]/EC(s) will be followed. Involvement of the national competent 
authorities (e.g. by [INVESTIGATOR_520383], seeking authoriza tion) will be accomplished as required by 
[CONTACT_690382]. 
  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 59 of 67 
  
 
15.0 R EFERENCES  
 
1. Sørbye, L. W., Finne‐Soveri, H., Ljunggren, G., Topi[INVESTIGATOR_690348], E., Garms‐Homolova, V., 
Jensdóttir, A. B., ... & AdHOC Project Research Group. (2009). Urinary incontinence and use of pads –clinical features and need for help in home care at 11 sites in Europe. 
Scandinavian journal of caring sciences, 23(1), 33- 44. 
2. Drennan, V. M., Cole, L., & Iliffe, S. (2011). A taboo within a stigma? A qualitative study of managing incontinence with people with dementia living at home. BMC geriatrics , 11(1), 1 -7. 
3. Drennan, V. M., Greenwood, N., Cole, L., Fader, M., Grant, R., Rait, G., & Iliffe, S. 
(2012). Conservative interventions for incontinence in people with dementia or cognitive 
impairment, living at home: a systematic review. Bmc Geriatrics , 12(1), 1 -10. 
4. Beer, J. M., McBride, S. E., Mitzner, T. L., & Rogers, W. A. (2014). Understanding challenges in the front lines of home health care: a human- systems approach. Applied 
Ergonomics , 45(6), 1687 -1699. 
5. Kuil, S. D., Hidad, S., Fischer, J. C., Visser, C. E., van Leth, F., de Jong, M. D., & 
Schneeberger, C. (2021). Diapers as Promising Alternative Collection Method for Urine Specimens in Nursing Home Residents: A Noninferiority Study. Journal of the American Medical Directors Association, 22(6), 1222- 1227.  
6. Hawkins, K., Pernarelli, J., Ozminkowski, R. J., Bai, M., Gaston, S. J., Hommer, C., ... & Yeh, C. S. (2011). The prevalence of urinary incontinence and its burden on the quality of life among older adults with medicare supplement insurance. Quality of life research , 
20(5), 723- 732. 
7. Li, Y., Cai, X., Glance, L. G., & Mukamel, D. B. (2007). Gender differences in healthcare- seeking behavior for urinary incontinence and the impact of socioeconomic 
status: a study of the Medicare managed care population. Medical care, 1116- 1122. 
8. Mardon, R. E., Halim, S., Pawlson, L. G., & Haffer, S. C. (2006). Management of urinary incontinence in Medicare managed care beneficiaries: results from the 2004 Medicare 
Health Outcomes Survey. Archives of internal medicine, 166(10), 1128- 1133. 
9. Samuelsson, E., Victor, A., & Tibblin, G. (1997). A population study of urinary 
incontinence and nocturia among women aged 20‐59 years. Acta obstetricia et 
gynecologica Scandinavica, 76(1), 74 -80. 
10. Bresee, C., Dubina, E. D., Khan, A. A., Sevilla, C., Grant, D., Eilber, K. S., & Anger, J. 
T. (2014). Prevalence and correlates of urinary incontinence among older, community-
dwelling women. Female pelvic medicine & reconstructive surgery, 20(6), 328. 
11. Goode PS, Burgio KL, Redden DT, et al. Population based study of incidence and predictors of urinary incontinence in black and white older adults. J Urol. 
2008;179:1449–1453. discussion 1453–1444. 
12. Beeckman, D. (2017). A decade of research on incontinence -associated dermatitis (IAD): 
evidence, knowledge gaps and next steps. Journal of tissue viability , 26(1), 47- 56. 
13. Coyne, K. S., Wein, A., Nicholson, S., Kvasz, M., Chen, C. I., & Milsom, I. (2014). 
Economic burden of urgency urinary incontinence in the [LOCATION_002]: a systematic 
review. Journal of Managed Care Pharmacy, 20(2), 130- 140. 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 60 of 67 
 14. Dramé, M., Fierobe, F., Lang, P. O., Jolly, D., Boyer, F., Mahmoudi, R., ... & Novella, J. 
L. (2011). Predictors of institution admission in the year following acute hospi[INVESTIGATOR_690349]. The journal of nutrition, health & aging, 15(5), 399-403. 
15. Sura, S., Shiozawa, A., Ng, D., & Aparasu, R. R. (2021). Higher resource utilization and costs in long-term nursing home residents with overactive bladder: a retrospective study of medicare beneficiaries. Journal of the American Medical Directors Associati on, 22(6), 
1300-1306. 
16. T.W. Hu, T.H. Wagner, J.D. Bentkover, et al. Costs of urinary incontinence and overactive bladder in the [LOCATION_002]: A comparative study. Urology, 63 (2004), pp. 461-465 
17. M.L. Ganz, A.M. Smalarz, T.L. Krupski, et al. Economic costs of overactive bladder in the [LOCATION_002]. Urology, 75 (2010), pp. 526-532.e1–[ADDRESS_936529] for patients with incontinent overactive bladder treated with anticholinergics. J Manag Care Spec Pharm, 22 (2016), pp. 406-[ADDRESS_936530] of coexisting overactive bladder in medicare patients with osteoporosis. Arch Gerontol Geriatr, 75 (2018), pp. 44-[ADDRESS_936531] costs associated with overactive bladder within a commercially -insured population in the [LOCATION_002]. J 
Occup Environ Med, 60 (2018), pp. 847-852 
22. E. Durden, D. Walker, S. Gray, et al. The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age- related comorbidities in the 
[LOCATION_002]. Neurourol Urodyn, 37 (2018), pp. 1641-1649 
23. Welk, B., & Kennelly, M. (2022). The relative importance of different consequences of nocturnal enuresis among older women: A conjoint analysis experiment. Neurourology and Urodynamics, 41(6), 1451-1457. 
24. Khosla, L., Sani, J. M., & Chughtai, B. (2022). Patient and caretaker satisfaction with the PureWick system. The Canadian Journal of Urology, 29(4), [ZIP_CODE]-[ZIP_CODE].  
25. Abraham, L., Hareendran, A., Mills, I. W., Martin, M. L., Abrams, P., Drake, M. J., ... & Noble, J. G. (2004). Development and validation of a quality-of- life measure for men 
with nocturia. Urology , 63(3), 481-486.  
26. Mock, L. L., Parmelee, P. A., Kutner, N., Scott, J., & Johnson II, T. M. (2008). Content validation of symptom- specific nocturia quality -of-life instrument developed in men: 
issues expressed by [CONTACT_31267], as well as men. Urology , 72(4), 736-742.  
27. Takao, T., Tsujimura, A., Kiuchi, H., Takezawa, K., Okuda, H., Yamamoto, K., ... & Nonomura, N. (2013). Correlation between overactive bladder symptoms and quality of life in Japanese male patients: focus on nocturia. Urology , 82(1), 189-193.  
28. Incontinence urinaire. (n.d.-b). Urofrance. 
https://www.urofrance.org/patient/pathologies-
urologiques/incontinence- urinaire/  
29. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, Amtmann D, Bode R, Buysse D, Choi S, Cook K, Devellis R, DeWalt D, Fries JF, Gershon R, Hahn EA, Lai JS, Pi[INVESTIGATOR_3708] P, Revicki D, Rose M, Weinfurt K, Hays R; PROMIS Cooperative Group. The Patient -Reported Outcomes Measurement Information System (PROMIS) developed and 
tested its first wave of adult self -reported health outcome item banks: 2005-2008. J Clin 
Epi[INVESTIGATOR_5541]. 2010 Nov;63(11):1179-94. doi: 10.1016/j.jclinepi.2010.04.011. Epub 2010 Aug 4. PMID: 20685078; PMCID: PMC2965562.  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 61 of 67 
  
16.0 A PPENDICES  
 
Appendix 1 : Draize Scale for Skin Irritation  
 
Draize Scale for Skin Irritation  
 
 
 Reference:  Draize J.H., Woodward G., Calvery H.O. Method for the study of irritation and toxicity of substances applied topi[INVESTIGATOR_497219]. J Pharmacol Exp Ther.  1944; 82: 377-390 
 
Appendix 2: K atz ADL assessment Score 
Appendix 3: PureWick ™ Female External Catheter Instructions for Use PWFX 30 (US)  
Appendix 4: PureWick ™ Female External Catheter Instructions for Use PW FX30E (EU)  
Appendix 5: PureWick ™ Urine Collection System Instructions for Use PW100 & PW 200 
(US) 
Appendix 6: PureWick ™ Urine Collection System Instructions for Use PW 200E (EU)  
Appendix 7: Hollister® Female Urinary Pouch  External Collection Device Instructions for 
Use  
 Score  Erythema (redness)  Edema (swelling)  Bleeding  
0 None  None  None  
1 Very slight (barely 
perceptible) erythema  Very slight (barely 
perceptible) skin surface rise  Just a visible spot of red  
2 Well-defined erythema Well-defined skin surface rise 
(edges of area well -defined by 
[CONTACT_363681])  A drop of red blood 
3 Moderate erythema  Moderate skin surface rise  A continuing ooze of red 
blood  
4 Severe (beet red) or 
damage to skin (eschar 
formation)  Severe skin surface rise  Significant bleeding from 
the sight 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 62 of 67 
 Appendix 8: N- QOL  English  
Appendix 9: N- QOL French  
Appendix 10: PROMIS English  
Appendix 11: PROMIS  French  
Appendix 12 : Participant Comfort Questionnaire PureWick ™ System (Sample)  
 
Participant Number:  Visit#:  
Now that you have experienced  the use of  each device  as well as voiding with the device in 
place, please answer  the following questions. 
1.  On a scale of 1 to 5 where 1 is very uncomfortable  and 5 is very comfortable, how 
comfortable was the placement  of the PureWick ™ Female External Catheter ? 
1 
Very 
uncomfortable 2 
Uncomfortable 3 
Neither 
comfortable nor 
uncomfortable 4 
Comfortable 5 
Very 
Comfortable 
Comments:  
 
2.  On a scale of 1 to 5 where 1 is very uncomfortable  and 5 is very comfortable, how 
comfortable was the PureWick ™ System  during sleep? 
1 
Very 
uncomfortable 2 
Uncomfortable 3 
Neither 
comfortable nor 
uncomfortable 4 
Comfortable 5 
Very  
Comfortab le 
Comments:  
 
3.  On a scale of 1 to 5 where 1 is very uncomfortable  and 5 is very comfortable, how 
comfortable was the removal  of the PureWick ™ Female External Catheter ? 
1 
Very 
uncomfortable 2 
Uncomfortable 3 
Neither 
comfortable nor 
uncomfortable  4 
Comfortable 5 
Very 
Comfortable 
Comments:  
 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 63 of 67 
  
4.  On a scale of 1 to 5 where 1 is very unlikely and 5 is very likely, how likely would you be to 
recommend the PureWick ™ System  to one of your loved ones? 
1 
Very unlikely 2 
Unlikely  3 
Neither likely 
nor unlikely  4 
Likely  5 
Very Likely  
Comments:  
 
 
 
  
Appendix 13 : Participant Comfort Questionnaire Hollister® Female Urinary Pouch 
External Collection Device (Sample)  
 
Participant Number:  Visit#:  
Now that you have experienced  the use of  each device  as well as voiding with the device in 
place, please answer  the following questions. 
1.  On a scale of 1 to 5 where 1 is very uncomfortable  and 5 is very comfortable, how 
comfortable was the placement  of the Hollister® Female Urinary Pouch External Collection 
Device ? 
1 
Very 
uncomfortable 2 
Uncomfortable 3 
Neither 
comfortable nor 
uncomfortable 4 
Comfortable 5 
Very 
Comfortable 
Comments:  
 
2.  On a scale of 1 to 5 where 1 is very uncomfortable and 5 is very comfortable, how 
comfortable was the Hollister® Female Urinary Pouch External Collection Device during 
sleep ? 
1 
Very 
uncomfortable 2 
Uncomfortable 3 
Neither 
comfortable nor 
uncomfortable 4 
Comfortable 5 
Very  
Comfortab le 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 64 of 67 
 Comments:  
 
3.  On a scale of 1 to 5 where 1 is very uncomfortable  and 5 is very comfortable, how 
comfortable was the removal  of the Hollister® Female Urinary Pouch External Collection 
Device ? 
1 
 
Very 
uncomfortable 2 
 
Uncomfortable 3 
 
Neither 
comfortable nor 
uncomfortable 
 4 
 
Comfortable 5 
 
Very 
Comfortable 
Comments:  
 
 
4.  On a scale of 1 to 5 where 1 is very unlikely and 5 is very likely, how likely would you be to 
recommend the Hollister® Female Urinary Pouch External Collection Device  to one of your 
loved ones?  
1 
Very unlikely 2 
Unlikely  3 
Neither likely 
nor unlikely  4 
Likely  5 
Very Likely  
Comments:  
 
 
 
 
Appendix 14 : PureWick ™ System Participant Ease of Use Questionnaire (Sample)  
 
Participant Number:  
 Visit #:  
1. On a scale of 1 to 5 where 1 is very difficult and 5 is very easy, how easy was the  set up 
and placement  of the PureWick ™ System ? 
1 
Very difficult  2 
Somewhat 
difficult 3 
Average 
difficulty  4 
Somewhat easy  5 
Very easy  
Comments:  
 
2. On a scale of 1 to 5 where 1 is very difficult and 5 is very easy, how easy was 
the removal  of the PureWick ™ FEC ? 
1 2 3 4 5 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 65 of 67 
 Very difficult  Somewhat 
difficult Average 
difficulty  Somewhat easy  Very easy  
Comments:  
 
3. How would you describe the dryness experience d with the PureWick ™ System during 
sleep ? 
1 
Never Dry 
(unacceptable)  2 
Some times  Dry 
(unacceptable)  3- 
Usually Dry  
(acceptable)  4 
Always  Dry to 
mostly always dry  
(acceptable)  
Comments:  
 
 
Appendix 15: Hollister® Female Urinary Pouch External Collection Device Participant 
Ease of use Questionnaire (Sample)  
 
Participant Number:  
 Visit #:  
1. On a scale of 1 to 5 where 1 is very difficult and 5 is very easy, how easy was 
the placement  of the  Hollister® Female Urinary Pouch External Collection Device ? 
1 
Very difficult  2 
Somewhat 
difficult 3 
Average 
difficulty  4 
Somewhat easy  5 
Very easy  
Comments:  
 
2. On a scale of 1 to 5 where 1 is very difficult  and 5 is very easy, how easy was 
the removal  of the  Hollister® Female Urinary Pouch External Collection Device ? 
1 
Very difficult  2 
Somewhat 
difficult 3 
Average 
difficulty  4 
Somewhat easy  5 
Very easy  
Comments:  
 
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date :   16 Apr 2024  
Page 66 of 67 
 3. How would you describe the dryness experienced with the Hollister® Female Urinary 
Pouch External Collection Device  during sleep?  
1 
Never Dry 
(unacceptable)  2 
Some times  Dry 
(unacceptable)  3 
Usually Dry  
(acceptable)  4 
Always  Dry to 
mostly always dry  
(acceptable)  
Comments:  
 
Appendix 16: End of Study Participant Preference Survey  (Sample)  
 
Participant Number:  
   
Thank you for participating in this study. Now that you have experienced the use of two urine 
collection devices, please answer a few questions about your experiences with the devices.  
 
As a reminder, during the study, you used two devices overnight while sleepi[INVESTIGATOR_007]:  During the first part of the study, you used the PureWick™ Urine Collection System/Hollister 
Female Urinary Pouch External Collection Device.  
 
During the second part of the study, you used the PureWick™ Urine Collection 
System/Hollister Female Urinary Pouch External Collection Device.  
 
 
 
1. Do you remember using each of these devices?  
__________ Yes  
__________ No  
<If No or if there is significant difficulty in differentiating the 2 study phases, discontinue the 
interview.>  
  
Protocol Number:  UCC- 8007   CONFIDENTIAL  
Version:  5.0 
Date:   16 Apr 2024  
Page 67 of 67 
  
2. Which device did you prefer?  
__________ PureWick™ Urine Collection System 
__________ Hollister® Female Urinary Pouch External Collection Device  
 
3. What made you choose the <PureWick/Hollister> device? Why did you prefer that device? ________________________________________________________________________  <Ask follow -up questions, as much as practical, to better understand the participant’s 
preference>  
 
4. Please think about how your skin felt when using each device. Which caused you to feel 
LESS skin irritation, the PureWick ™ device or Hollister® device? 
__________ PureWick™ Urine Collection System __________ Hollister® Female Urinary Pouch External Collection Device __________ No difference __________ Do not recall  Why did you choose the PureWick/Hollister? __________________________________________________________________________________________________________________________________________________________________________________________________________________   Thank you for taking the time to answer these questions!   